Oncology for the Inquisitive Mind

196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS

Thu, 09 Apr 2026 05:57:31 GMT

UPDATED WITH CORRECT AUDIO

While Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF mutations in colorectal cancer were historically prognostic; this has now shifted with targeted therapies available for both. In the context of metastatic colorectal cancer, BRAF mutations account for up to 10% of cases and are associated with significantly poorer overall survival compared with wild-type (WT) counterparts. The median overall survival in many cases of metastatic disease was under 15 months. Five years ago, there were no options, but now we see a growing list of potential therapeutic choices. Trials discussed today include BREAKWATER and CODEBREAK 300.

Studies discussed in this episode:

BREAKWATER

Codebreak 300

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

195. Back to Basics - Immunotherapy in Metastatic Colorectal Cancer

Sat, 28 Mar 2026 22:45:03 GMT

Historically, colorectal cancer treatment has been fairly standard, but this has shifted over the past decade with the introduction of targeted therapies. This week, our focus is on patients with microsatellite instability (dMMR) colorectal cancer, a small but meaningful cohort. This condition affects up to 15% of patients, many of whom carry germline mutations in the MLH1 and MSH2 genes, which simply means that cells can't recognise and fix spontaneous mutations. Historically, these cancers are less responsive to chemotherapy.

This week, we explore two immunotherapy regimens - pembrolizumab, ipilimumab and nivolumab.

Studies discussed in this episode:

Checkmate 8HW

KEYNOTE-177

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

194. Back to Basics - Metastatic Colorectal Cancer

Sat, 21 Mar 2026 13:00:00 GMT

Metastatic colorectal cancer is one of the leading causes of cancer-related deaths and among the most common types of cancer worldwide. Chemotherapy remains the main treatment, but the question is: how can we make it more effective without increasing toxicity?

This week, we explore the intensification of chemotherapy in an effort to improve overall survival. The second topic involves the use of monoclonal antibodies and targeted therapy to enhance existing regimens. Josh also conducts his characteristic deep dive, examining the evolution and application of the monoclonal antibodies cetuximab and panitumumab over the past 15 years. He aims to answer the long-standing question: does one size fit all for colorectal cancers?

Studies discussed in this episode:

FOLFOXIRI

Beva/Cetux

FIRE-3 Trial

TAILOR Trial

Crystal

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

193. Genitourinary Cancers and Prof Jonathan E Rosenberg MD

Sat, 14 Mar 2026 13:00:00 GMT

Professor Jonathan E. Rosenberg, MD, serves as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Centre (MSKCC). He is a prolific researcher and author, holding multiple titles including Attending Physician at MSKCC, Professor of Medicine at Weill Cornell Medical College, and the Enno W. Ercklentz Chair in Genitourinary Oncology.

Today, Jonathan explores metastatic urothelial cancer, discussing the current landscape and available treatment options, emphasising that a single approach may not be suitable for all patients. We also cover early bladder cancer and non-invasive muscle-invasive bladder cancer (NIMBC).

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

192. Back to Basics - Early Colorectal Cancer - Part 2!

Sat, 07 Mar 2026 13:00:00 GMT

The DYNAMIC duo are back, with Michael climbing the "Everest" of oncology and exploring the role of CTDNA in stage two colorectal cancer. Josh has the easier job of exploring neoadjuvant immunotherapy (ipilimumab and nivolumab) in dMMR advanced colorectal cancer.

Both are excellent trials, and a worthy addition to your reading list.

Don't forget to check us out on YouTube if that's your thing!

Studies discussed in this episode:

DYNAMIC-II

NICHE-2

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

191. Back to Basics - Early Colorectal Cancer

Sat, 28 Feb 2026 13:00:00 GMT

This week, we explore early colorectal cancer. Maybe it’s just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or CAPOX. Josh digs a bit deeper and, as the name suggests, looks at whether patients with liver metastases can be cured with chemotherapy and a liver transplant.

Studies discussed in this episode:

IDEAS

TransMET

EORTC

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

190. Back to Basics - Mesothelioma

Sat, 21 Feb 2026 13:00:00 GMT

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.

Studies discussed in this episode:

MAPS

Checkmate 743

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

189. Back to Basics - Extensive Stage Small Cell Lung Cancer

Mon, 16 Feb 2026 04:01:48 GMT

This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a faster rate than in the last twenty years combined.

We explore tarlatamab, a bispecific delta-like ligand 3-directed T cell engager. The results show that, in the second-line setting, it improves overall survival (spoiler alert). The second study is IMforte, utilising lurbinectedin plus atezolizumab in the first-line setting for extensive-stage SCLCa. Again, a positive trial showing an improved median overall survival of 13.2 months vs 10.6 months, but does the toxicity profile trade off support this modest OS benefit? Tune in to find out!

Studies discussed in this episode:

Imforte

DeLLphi-304

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

188. Gastrointestinal Cancer and Professor Jenny Seligmann

Wed, 11 Feb 2026 02:55:37 GMT

Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, is renowned for leading the groundbreaking FOxTROT and ARIEL trials. These studies challenged traditional practices by demonstrating the advantages of administering chemotherapy before surgery, a change now saving lives and influencing worldwide protocols. As a devoted mentor and a prominent participant in Cancer Research UK’s initiatives, she joins us to explore how we can personalise cancer treatment more effectively and discuss the future prospects for gastrointestinal cancer therapies. Welcome, Professor Seligmann.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

187. ESMO Awards - Episode 7

Mon, 02 Feb 2026 23:47:38 GMT

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG in non-muscle invasive bladder cancer, adjuvant durvalumab in renal cell caricnoma and the perioperaive role of enforumab vedotin for muscle invasive bladder cancer.

We're out of breath just listing off these trials, and if this hasn't gotten you excited, then probably nothing will!

See you next week, where we interview our spectacular guest Professor Jenny Seligmann, who will bring you up to date on Michael's favourite topic, colorectal cancers!

Studies:

IMvigor011 (NCT04660344)

KEYNOTE 905/EV-303 (NCT03924895)

POTOMAC (NCT03528694)

ARASAFE (NCT02799602)

RC48-C016 (NCT05302284)

PSMAddition (NCT04720157)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

186. ESMO Awards - Episode 6

Sun, 25 Jan 2026 00:36:24 GMT

ESMO Episode 6 is here! The longest award ceremony in the world continues. This episode covers colorectal cancer, a cancer stream that has relied heavily on the same three drugs for the past twenty-five years.

We cover the golden pinnacle of real-world use cases for CTDNA, neoadjuvant immunotherapy in those with proficient MMR colorectal cancer, whether Zanzalimab helps in refractory colorectal cancer, and much more.

Studies:

BREAKWATER

NEOADJUVANT IMMUNOTHERAPY (pMMR)

STELLAR-303

CHECKMATE 8HW

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

185. ESMO Awards - Episode 5

Wed, 21 Jan 2026 05:30:50 GMT

We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers.

This episode covers FGFR inhibitors (Bemartizumab), updates on the MATTERHORN trial, the use of immunotherapy with trastuzumab and FLOT in HER2-positive localised oesophageal carcinoma, and investigates the use of TKIs and the novel drug nofazinlimab for those with unresectable or metastatic hepatocellular carcinoma.

A jam-packed episode that aims to over-deliver on information, laughter, and hope.

2026 is going to be a big one!

Studies:

FORTITUDE-101

MATTERHORN

PHERFLOT/IKF-053

NCT04669496

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

184. ESMO Awards - Episode 4

Sat, 13 Dec 2025 19:00:00 GMT

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.

Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial.

Studies:

LITESPARK-15

IMPRESS-Norway trial

Abstract 1510M0

BNT111 (NCT04526899)

Safe Stop Trial

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

183. ESMO Awards - Episode 3

Fri, 05 Dec 2025 00:03:13 GMT

For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.

Studies:

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

182. ESMO Awards - Episode 2

Wed, 26 Nov 2025 03:56:53 GMT

ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.

Studies:

TROPION-Breast02 trial

ROSELLA

DICE trial

ENGOT-ov65/KEYNOTE-B96 study

ROSELLA

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

182. ESMO Awards - Episode 1

Sat, 15 Nov 2025 20:00:00 GMT

After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmine that was this year's European Oncology Extravaganza.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

181. Back to Basics - Limited Stage Small Cell Lung Cancer

Sat, 18 Oct 2025 20:00:00 GMT

In this episode, the focus shifts away from the more "garden-variety" non-small cell lung cancer and to its less common, frequently more aggressive sibling, small cell lung cancer. Here, Josh and Michael examine the management of limited-stage small cell lung cancer, which while accounting for a minority of cases, is no less interesting and potentially confusing.

Studies discussed in this episode:

PCI Meta Analysis

ADRIATIC

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

180. Back to Basics - Metastatic NSCLC feat. KRAS and MET mutations

Sun, 12 Oct 2025 10:06:27 GMT

On this week's episode, Josh and Michael exchange the established treatment landscape of EGFR and ALK mutant NSCLC for the developing management of disease harbouring KRAS and MET mutations. The most common mutation meets one of the least common in this battle of therapeutic tenacity.

Studies discussed in this episode:

INSIGHT-2

KRYSTAL-12

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

179. Back to Basics - Metastatic NSCLC feat. EGFR and ALK Driver Mutations

Sun, 05 Oct 2025 07:51:26 GMT

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? You'll just have to listen and find out.

Studies discussed in this episode:

MARIPOSA

CROWN

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

178. Back to Basics - Metastatic Non Small Cell Lung Cancer (mNSCLCa)

Sat, 27 Sep 2025 20:00:00 GMT

Advanced or Metastatic Non Small Cell Lung Cancer (mNSCLCa), is one of the most common causes of death worldwide. This week, Michael provides an excellent background on this type of cancer, and Josh provides an eloquently short introduction (for once). These trials look specifically at lung cancers without mutations, thus relying on immunotherapy and chemotherapy.

As a side note, can you believe Keynote189 is over 7 years old! How time flies!

Studies discussed in this episode:

Keynote 189

Checkmate 9LA

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

177. Back to Basics - Early Non Small Cell Lung Cancer

Sat, 13 Sep 2025 20:00:00 GMT

To Josh's immense displeasure, our series on genitourinary cancer is done. For now, at least. In this episode, Michael and Josh step into the heavy shadow of non-small cell lung cancer, the most common cause of cancer death in Australia. However, there is hope and new developments in the early-disease space that could significantly improve outcomes.

Studies discussed in this episode

Checkmate 816

neoADAURA

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

176. Back to Basics - Germ Cell Tumours (part 2)

Sat, 06 Sep 2025 23:07:56 GMT

In this episode, Michael and Josh continue to unpick the thorny question of germ-cell tumours, focusing this week on more advanced and relapsed disease. Germ cell tumours have an excellent prognosis, but unfortunately there are cases where more intense therapy is required. Listen on to find out about what to do when first line therapy is not enough!

Studies discussed in this episode

BEP - Williams et al (1987)

TIP - Gleeson et al (20224)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

175. Back to Basics - Germ Cell Tumours (part 1)

Sat, 30 Aug 2025 20:00:00 GMT

This episode is the first of a two-part mini-series where Michael and Josh attempt to untangle the complex topic of germ cell tumours, an area that requires specialist experience and a high-volume multi-disciplinary centre to treat adequately. Or, you could just listen to Oncology for the Inquisitive Mind and be a pro in no time!

Studies discussed in this episode

EORTC-30982

de Wit et al (2001)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

174. Back to Basics - Non Clear-Cell Renal Cell Cancer (RCC)

Sun, 24 Aug 2025 10:02:10 GMT

In this episode, Josh and Michael take a trip down a road less travelled by both patients and researchers, and examine the evidence (or lack thereof) of non-clear cell renal cell cancer, a less common cluster of siblings to the much better established clear cell RCC. Treatment is on very similar patterns, so their studies today involve a lot of immunotherapy with a smattering of tyrosine kinase inhibitors.

Studies discussed in this episode

KEYNOTE-B61

Checkmate 920

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

173. NECTA (New South Wales Early Phase Clinical Trials Alliance) - The Origin Story

Sun, 17 Aug 2025 10:08:49 GMT

How do you increase access to phase 1 trials for a state with a population of 8 million people spread across 800,000 km^2? You collaborate! In this context, we explore NECTA. The New South Wales Early Phase Clinical Trials Alliance (NECTA) plays a key role in speeding up the translation of cutting-edge medical research into real-world treatments, providing vital benefits to patients and the broader healthcare system. By uniting a network of leading hospitals, research institutions, and clinical experts, NECTA streamlines trial coordination, shortens start-up times, and encourages collaboration between researchers and industry. This early-phase focus not only offers patients earlier access to promising new therapies but also positions NSW as a globally competitive hub for innovative clinical research—ultimately advancing medical science while boosting the state’s life sciences sector.

For more information: https://www.necta.org.au/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

172. Back to Basics - Advanced ccRCC

Sat, 09 Aug 2025 20:00:00 GMT

Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal disease, with a predilection for the CNS and significant bleeding risk has become significantly less so. In this episode, Josh and Michael explore the studies that have made it happen.

Studies discussed in this episode

CLEAR

Checkmate 214

Checkmate 9ER

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

171. Back to Basics - Early Clear Cell Renal Cell Cancer (ccRCC)

Sat, 02 Aug 2025 20:00:00 GMT

Continuing on their Back to Basics GU extravaganza, Josh and Michael progress to the subject of kidney cancer, and bring you the answer to a question long unanswered: is there any benefit of adjuvant therapy in resected clear cell renal cell cancer. For a long time, this space produced negative study after negative study, until, as is so often the case, immunotherapy swooped in to save the day.

Studies discussed in this episode

S-TRAC

KEYNOTE-564

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

170. Back to Basics - Adjuvant Urothelial Cancer

Sat, 26 Jul 2025 20:00:00 GMT

Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant management of urothelial cancer, focussing on the sometimes contradictory data of adjuvant immunotherapy. This is an emerging area of treatment that you will not want to miss!

Studies discussed in this episode

AMBASSADOR

Checkmate 274

IMvigor010

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

169. ASCO 2025 - Colorectal Cancer with Prof Jeanne Tie

Sat, 05 Jul 2025 20:00:00 GMT

In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Starting with the practice changing BREAKWATER study, combining chemotherapy with encorafenib and cetuximab, they also discuss the plenary study ATOMIC III, the CHALLENGE study examining structured exercise programs for patients with resected cancer, as well as the emerging role of ctDNA in colon and anal SCC.

Studies discussed in this episode

BREAKWATER

CHALLENGE

ATOMIC III

INTERAACT 2

DYNAMIC III

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

168. ASCO 2025 - Early Breast Cancer with Dr. Belinda Yeo

Thu, 03 Jul 2025 20:00:00 GMT

In this episode, Michael goes it alone, welcoming an old friend of the show, Dr Belinda Yeo, to discuss highlights in early breast cancer from ASCO 2025. The pair discuss an exciting new medication to assist with vasomotor symptoms from endocrine therapy, the ongoing follow up from the pivotal SOFT/TEXT study, an escalation strategy for abemaciclib and a de-escalation strategy for neoadjuvant chemotherapy in HER2 positive breast cancer.

Studies discussed in this episode

OASIS

SOFT/TEXT, 15 year update

TRADE

NeoCARHP

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

167. ASCO 2025 - Upper GI and Hepatobiliary Cancer with Dr. James McCracken

Mon, 30 Jun 2025 20:00:00 GMT

Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael repetitively insists) "big ticket": MATTERHORN and Destiny-Gastric04. In addition, James gives his thoughts on studies that look at immunotherapy and novel neoadjuvant chemotherapy in pancreatic cancer, and a small study examining a perioperative approach to resectable biliary tract cancer.

Studies discussed in the episode:

MATTERHORN

Destiny-Gastric04

NeoIMPACT

CASSANDRA

GAIN

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

166. ASCO 2025 - Gynecological Oncology with Dr. Prachi Bhave

Sat, 28 Jun 2025 03:36:34 GMT

Today, we discuss the latest advancements in gynecological oncology presented at ASCO 2025, featuring insights from Dr. Prachi Bhave. The conversation covers significant trials including the TRUST trial on ovarian cancer surgery timing, the Rosella trial for platinum-resistant ovarian cancer, the FIRST study on immunotherapy in advanced ovarian cancer, and the update on the Keynote A18 trial for cervical cancer. The discussion emphasizes the importance of these studies in shaping future treatment strategies and improving patient outcomes.

Studies discussed in the episode:

Trust study

FIRST/ENGOT-OV44

Rosella study (GOG-3073, ENGOT-ov72)

Keynote A18

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

165. ASCO 2025 - Palliative Care with Dr. Janet Abrahm

Mon, 23 Jun 2025 10:36:50 GMT

In this episode, Dr. Janet Abrahm shares transformative insights from ASCO 2025, focusing on palliative care and supportive care in oncology. Topics discussed include the role of exercise in cancer survival, cannabis use for symptom management, and the challenges of chemotherapy-induced peripheral neuropathy. We also highlight the importance of communication with patients, particularly in the context of grief and transition to palliative care, as well as the pervasive issue of burnout among oncology professionals.

Studies discussed in the episode:

Cannabis [Educational session re: ASCO 2024 Guideline; abstrs 120831; 12061]

Hot flashes [508]

Is local estrogen therapy safe for breast cancer survivors [578]

Duloxetine: Disappointing results [12010]

2021 study report [9005] with discussion of 2023 updates

Challenge Trial - Exercise extends life in Colon CA pts: already in NEJM and reported earlier in ASCO GI meeting LBA3510

AND MORE!

Check out Janet's page for more palliative care information: https://janetabrahm.com/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

164. ASCO 2025 - Lung Cancer with Dr. Ned McNamee

Sun, 22 Jun 2025 05:22:14 GMT

In this episode, Dr. Ned McNamee discusses the latest advancements in lung cancer treatment presented at ASCO 2025, focusing on significant studies such as the Phase 3 DeLLphi-304 study and Checkmate 816. They explore the implications of these findings for clinical practice, including the challenges of managing immune-related side effects and the potential for neoadjuvant immunotherapy to improve patient outcomes. The conversation also touches on the economics of oncology and the surprising results regarding the timing of immunotherapy administration.

Studies discussed in the episode:

Phase 3 DeLLphi-304

NeoADAURA

Checkmate816

IMFORTE study

Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.

AND MORE!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

163. ASCO 2025 - Genitourinary Cancers (Bladder and Renal) with Dr. Enrique Grande

Thu, 19 Jun 2025 05:08:31 GMT

Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins us.

This is a mega episode where we cover AMPLITUDE, JAVELIN MEDLEY, CHECKMATE 901 and NIAGARA, advancing urothelial cancer care; SEAR 02 and the CReST trial, pushing boundaries in bladder cancer; CHECKMATE 214; LITESPARK-005 and LITESPARK-004, showcasing belzutifan’s promise; and KEYNOTE-564, adjuvant therapy for kidney cancer. Stay tuned for an insightful conversation on how these trials may be transforming patient outcomes!

Studies discussed in the episode:

CHECKMATE 901

NIAGARA

CHECKMATE 214

CREST trial

SEAR 02

LITESPARK 004/005

AMPLITUDE

JAVELIN MEDLEY

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

162. ASCO 2025 - Genitourinary Cancers (Prostate) with Dr. Anthony Joshua

Mon, 16 Jun 2025 20:00:00 GMT

Today, we’re joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent’s Hospital, Sydney, and a global leader in prostate cancer and melanoma.

In this episode, Professor Joshua discusses multiple trials including AMPLITUDE, advancing prostate cancer therapies; CAN 2409, exploring immunotherapy; ARANOTE, showing darolutamide’s impact on progression-free survival; the prognostic significance of PSA 0.2; and the landmark STAMPEDE study. Join us for a deep dive into these game-changing studies. Let’s begin! It's a jam-packed episode!

Studies discussed in the episode:

AMPLITUDE

CAN2409

ARANOTE

STAMPEDE

*AND MORE!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

161. ASCO 2025 - Breast Cancer with Dr. Adam Brufsky

Sun, 15 Jun 2025 05:16:54 GMT

In this episode, we unpack game-changing insights from ASCO 2025 with a spotlight on breast cancer. Joining us is Dr. Adam Brufsky, a trailblazing oncologist and professor at the University of Pittsburgh, with 30 years of experience, whose expertise has helped shape the direction of treatment.

Trials discussed include the SERENA-6 trial, which examines camizestrant plus CDK4/6 inhibitors in HR-positive, ESR1 mutation breast cancer; the DESTINY-Breast09 trial, highlighting trastuzumab deruxtecan in combination with pertuzumab; and the INAVO120 trial, revealing inavolisib’s triplet therapy response in PIK3CA-mutated, HR-positive, HER2-negative disease. Join us for a deep dive into these game-changing findings and their impact on patient care.

Studies discussed in the episode:

SERENA-6

DESTINY BREAST 09

INAVO 120

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

160. ASCO 2025 - Plenary Part 2

Wed, 11 Jun 2025 23:46:50 GMT

In our second plenary episode, we're spotlighting two pivotal phase 3 trials: SERENA-6, which explores ctDNA-guided treatment with camizestrant to delay progression in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, and NIVOPOSTOP, a landmark study showing improved disease-free survival with adjuvant nivolumab in high-risk, resected head and neck squamous cell carcinoma. Join us as we unpack these practice-changing findings with expert insight and a couple of dad jokes along the way.

Studies discussed in the episode:

SERENA-6

NIVOPOSTOP

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

159. ASCO 2025 - Plenary Part 1

Sat, 07 Jun 2025 20:00:00 GMT

This year, Michael and Josh bring you the American Society of Clinical Oncology (ASCO) 2025. To keep it fresh, we're doing things a little differently, but rest assured, we'll bring along a global host of experts to deliver the very best from the practice-changing, thought-provoking, design-defining trials you know and love from this podcast.

This episode focuses on adjuvant atezolizumab in the colon cancer space and the use of perioperative durvalumab in the gastric cancer space. Both are exciting spaces and have the potential to be practice-changing.

Don't forget to like and subscribe if you love what we do!

Studies discussed in the episode:

ATOMIC

MATTERHORN

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

158. Back to Basics - Metastatic Urothelial (Bladder) Cancer

Sat, 31 May 2025 20:00:00 GMT

This week, we talk about metastatic bladder cancer. The last two years have seen drastic changes in this space, with the addition of immunotherapy and ADCs in a first-line setting. While exceptionally effective, toxicity and patient selection remain challenging. The other big issue with what's best for the second line? That's the golden question.

Studies discussed in the episode:

EV-302

THOR

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

157. Back to Basics - Early Bladder Cancer

Sat, 24 May 2025 20:00:00 GMT

This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regimens. The key to this trial may be the amount of cisplatin delivered, but there are some unknowns in a real-world setting. It also compared the neoadjuvant to the perioperative space. The second trial utilises immunotherapy in the perioperative landscape and is the first trial to so but only used one chemotherapy regimen.

A must-listen to episode comparing the complexities of early bladder cancer and the options available.

Studies discussed in the episode:

VESPER

NIAGARA

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

156. Back to Basics - Prostate Cancer - Biochemical Recurrence and Oligometastatic Disease Control

Sat, 17 May 2025 20:00:00 GMT

As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in tumour-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Both excellent studies raise the question of newer technologies and how we apply this information to trials that already exist.

Studies discussed in the episode:

EMBARK

SOLAR/SATURN

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

155. Back to Basics - Theranostics and Prostate Cancer

Sat, 10 May 2025 20:00:00 GMT

Marie Curie's life work laid the foundations for theranostics. This week, we talk about Lutetium, a rare earth metal, and its role in Prostate Cancer. Lutetium-177 PSMA therapy is a radiation therapy that targets prostate cancer. It is used in the advanced, metastatic, and castrate-resistant space. Lutetium is bound to a protein called PSMA. PSMA is overexpressed in many prostate cancers and can be used to target these cancer cells via the membrane antigen.

Studies discussed in the episode:

UpFrontPSMA

VISION trial (and a bit on TheraP)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

154. Back to Basics - Non Metastatic and Metastatic Prostate Cancer - The Journey Continues

Sat, 03 May 2025 20:00:00 GMT

Prostate Cancer has a multitude of presentations, but when metastatic, it usually spreads directly to the lymph nodes or the bones. This episode focuses on the contentious definition of "M0 Castrate Resistant Prostate Cancer (CRPC)", also known as Nonmetastatic CRPC. Does this definition exist, and what role will PSMA PET have in this cohort of patients? The second trial, TITAN looks at apalutamide, another ARPI/ARSI and how it compares to it's cousins who are fighting for the top spot in the prostate cancer world.

Studies discussed in the episode:

ARAMIS

TITAN

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

153. Inflammatory Breast Cancer with Dr Massimo Cristofanilli, M.D.

Sat, 26 Apr 2025 20:00:00 GMT

This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contributions to translational research, he has transformed the way we approach metastatic breast cancer, leading advances in liquid biopsy, molecular profiling, and targeted therapies.

Dr Cristofanilli serves as the Director of Breast Medical Oncology, Associated Director of Precision Oncology at the Meyer Cancer Centre, and co-leader of the MCC Breast Cancer Disease Management team, in addition to being the Scientific Director of the Englander Institute of Precision Medicine.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

152. Back to Basics - High Volume Metastatic Prostate Cancer

Sat, 05 Apr 2025 20:00:00 GMT

Today, we discuss the role of triplet therapy (ie, chemotherapy and androgen receptor signalling inhibitor and ADT) in high-volume metastatic hormone-sensitive prostate cancer and whether darolutamide is equivalent to the other androgen receptor signalling inhibitors in the castrate-sensitive space. Two good trials, and as always, some interesting discussion points.

Studies discussed in the episode:

ARASENS

ARANOTE

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

151. Back to Basics - Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer

Sat, 29 Mar 2025 19:00:00 GMT

The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents.

Studies discussed in the episode:

ARCHES

ENZAMET

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

150. Back to Basics - Recurrence-Score Assays in Early Breast Cancer

Sat, 22 Mar 2025 19:00:00 GMT

Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episode, but we explore the role of Oncotype Dx!

Studies discussed in the episode:

TAILORx

RxPonder

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

149. Back to Basics - Metastatic Hormone Sensitive Prostate Cancer

Sat, 15 Mar 2025 19:00:00 GMT

This week, we prematurely dive into prostate cancer (one breast episode remaining - whoops!), where we explore the early pivotal trials, including the role of abiraterone in metastatic hormone-sensitive prostate cancer and the use of docetaxel in high and low-volume prostate cancer.

Studies discussed in the episode:

LATITUDE

STAMPEDE

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

148. Back to Basics - Metastatic Triple Positive (HER2) Breast Cancer

Sat, 08 Mar 2025 19:00:00 GMT

As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target both antibody-drug conjugate therapy and targeted therapy (trastuzumab deruxtecan and pertuzumab). While HER2-positive cancer's survival is one of the best for metastatic disease, this was not always the case.

Studies discussed in the episode:

DESTINY 03

CLEOPATRA Trial

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

147. Back to Basics - Metastatic Triple Negative Breast Cancer

Sat, 01 Mar 2025 19:00:00 GMT

Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway!

Studies discussed in the episode:

KEYNOTE 355

ASCENT

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

146. Back to Basics - BRCA mutation and Breast Cancer Management

Sat, 22 Feb 2025 19:00:00 GMT

It's been an "Olympic" ride to get here, and this is our penultimate breast cancer episode! Today, we talk about the BRCA mutations and how they impact both breast cancer and outcomes using targeted therapy. BRCA is a tumour suppressor gene.

Today, we explore olaparib and its role in the adjuvant and metastatic setting for breast cancer.

Studies discussed in the episode:

OLYMPIA

OLYMPIAD

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

145. Back to Basics - Metastatic Hormone Receptor Positive Breast Cancer

Sat, 15 Feb 2025 19:00:00 GMT

Metastatic Hormone Receptor-Positive Breast Cancer truly represents the frontier of Medical Oncology, with life expectancy creeping up to and beyond five years. This week, we discuss Monaleesa-2 (Ribociclib), Paloma-2 (Palbociclib) and, of course, highlight the importance of Monarch-3 (Abemaciclib). The great CDK debate continues, and while the phase three trials have a clear winner, it's important to discuss the benefits and cons of each.

Studies discussed in the episode:

MONALEESA-2

PALOMA-2

MONARCH-3 (Mention)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

144. Back to Basics - Early Triple Negative Breast Cancer

Sat, 08 Feb 2025 19:00:00 GMT

Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It represents about 15% of all breast cancers.

This week, we explore the benefit of immunotherapy (pembrolizumab), looking at improved complete pathological response as a surrogate marker for OS and the role of capecitabine in the adjuvant setting.

Studies discussed in the episode:

CREATE-X

KEYNOTE-522

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

143. San Antonio Breast Cancer Symposium 2024 - Part 2

Sat, 01 Feb 2025 19:00:00 GMT

Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024.

In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel ADC (SHR-A1811) and the role of tumour mutational burden in triple-negative cancer.

Studies discussed in the episode:

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

142. San Antonio Breast Cancer Symposium 2024 - Part 1

Sun, 26 Jan 2025 01:25:22 GMT

Welcome back to Oncology for the Inquisitive Mind, where we head back to late 2024 and cover some pivotal trials and ideas from the San Antonio Breast Cancer Conference 2024.

This episode broadly covers hormone receptor-positive breast cancer and looks at another CDK comparison (real-world data). While the idea is not new, the potential implications from well-gathered "phase 4" data is a curious discussion point. Other topics include the ESR1 mutation and Imlunestrant, Patritumab Deruxtecan in hormone receptor-positive disease and the role of CTDNA in tumour burden and recurrence in early breast cancer

Studies discussed in the episode:

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

141. Back to Basics - The role of endocrine therapy in Breast Cancer

Sat, 21 Dec 2024 19:00:15 GMT

Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as delay disease progression. This episode dives into a past of phenomenal improvement in the adjuvant breast cancer space. How long should one take endocrine therapy? We cover all the facts you need to know as a clinician or if you are curious from a patient/learning perspective.

Studies discussed in the episode:

EBCTCG Group - 2011 + 2015

ATLAS trial

BIG 198 trial

Patient-level meta-analysis of the randomised trials

IDEAL study

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

140. Back to Basics - Adjuvant HER2 Breast Cancer (Part 2)

Sat, 14 Dec 2024 19:00:26 GMT

HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditional chemotherapy, the landscape of everything we treat is slowly changing.

Studies discussed in the episode:

KATHERINE

PERSEPHONE

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

139. Back to Basics - Early HER2 Breast Cancer

Sun, 08 Dec 2024 01:48:39 GMT

Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and the complete picture is yet to be understood.

This week, we explore the original wonder drug (Trastuzumab) in the early breast cancer space and its compatriot, Pertuzumab. Josh highlights the association between pathological complete responses and event-free survival/overall survival, while Michael looks at Neosphere and picks apart the data to help understand where this drug is most beneficial.

Studies discussed in the episode:

NEOSPHERE

GEPARQUINTO

NOAH TRIAL

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

138. Back to Basics - Adjuvant CDK4/6 inhibitors in Early Breast Cancer

Sat, 30 Nov 2024 19:00:57 GMT

Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improvements are much harder to substantiate with the effect treatments currently on the market, but there is promise. This week, on our Back to Basics episode, Michael and Josh look at the role of abemaciclib and ribociclib in the adjuvant setting in patients with high-risk early breast cancer. Both of these drugs are CDK4/6 inhibitors and have been shows to be efficacious in the metastatic hormone receptor positive status breast cancer space.

This week we explore MONARCH-E and NATALEE and highlight the data and how it could impact CKD's role in this emerging landscape.

Studies discussed in the episode:

MONARCH-E

NATALEE

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

137. Back to Basics - High Risk Breast Cancer

Sat, 23 Nov 2024 19:00:43 GMT

Breast Cancer is complex, as are the treatment options that clinicians and patients must traverse. Stage III breast cancer has up to a 57% chance of recurring up to 20 years after diagnosis. Josh and Michael look at one of the practice-changing papers that tried to address how to manage high-risk patients. This study is called Soft and Text. It asked if adding ovarian suppression to aromatase inhibitors was better than ovarian suppression with selective estrogen receptor modulators (SERMs) to reduce the risk of recurrence in premenopausal women.

Studies discussed in the episode:

SOFT and TEXT

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

136. Evolving landscape of Genitourinary Cancers (Bladder Cancer) - Prof Enrique Grande

Sat, 16 Nov 2024 20:04:55 GMT

Prof Enrique Grande, a medical oncologist from Madrid, Spain, is our guest on Oncology for the Inquisitive Mind this week. Enrique is not your average oncologist nor your average podcast guest with a fascinating back story, a varied career and the charisma and wisdom to match!

Enrique has worked in all facets of oncology, including industry and is helping transform how patients access oncology care in Spain. He is the director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Centre Madrid. Prof Grande strongly focused on genitourinary and endocrine cancer research and was awarded his PhD in pharmacokinetic and pharmacodynamics study of tyrosine kinase inhibitors in liver metabolism.

Listen on, and you will learn all there is to know about bladder cancer and the world of medical oncology.

We explore the #NIAGARA trial, #EV302 and many other trials that are changing the face of bladder cancer!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Hosted on Acast. See acast.com/privacy for more information.

135. ESMO 2024 - Breast Cancer with Dr Adam Brufsky

Sat, 09 Nov 2024 19:00:24 GMT

In our final ESMO 2024 analysis this week, we bring back Dr. Adam Brufsky, "a giant among men (and women)" in breast cancer research and management. He discusses the field, the pivotal updates in ESMO, and what this means for patients. He also explores many of the unanswered questions.

Links to studies discussed in this episode (subscription may be required):

DESTINYBREAST012

KEYNOTE522

Many other pearls of wisdom - so tune in!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

134. ESMO 2024 - Lung Cancer with Dr Ned McNamee

Sat, 02 Nov 2024 19:00:48 GMT

Lung cancer treatment has changed seismically since 2018 and the NEJM publication of Keynote 189. This week, we have Dr. Ned Mcnamee on the show to give us his highlights of lung cancer updates from ESMO 2024. He explores the resectable lung cancer space with Checkmate-77T; crosses the ADRIATIC trial in patients with limited-stage small cell lung cancer, and brings in a home run with an updated LAURA trial mention (osimertinib after definitive chemoradiotherapy)

Links to studies discussed in this episode (subscription may be required):

Checkmate77T

ADRIATIC

LAURA

Special mentions

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

133. ESMO 2024 - Genitourinary Cancers with Prof Anthony Joshua

Sat, 26 Oct 2024 19:00:23 GMT

ESMO 2024 was the year genitourinary cancer took front and centre stage with many exciting updates, trials, and tribulations. This week, OFTIM brings their greatest champion back to dive deep into the changes that will impact our patients and their families, the NCCN guidelines, and how we practice medicine. Unfortunately, the heavyweight champion boxer was unavailable, but we got the next best thing - Prof Anthony Joshua from St Vincent's Health and The Garvan Institute of Medical Research. This week, he discusses all things genitourinary cancer and gives a knockout performance.

Enough boxing analogies - on with the show!

Links to studies discussed in this episode (subscription may be required):

PATCH+STAMPEDE

ARANOTE

STAMPEDE (metformin Arm)

PEACE-3

SPLASH

NIAGARA

AMBASSADOR

TiNivo-2

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

132. ESMO 2024 - Colorectal Cancer with Dr Geoffrey Chong

Sat, 19 Oct 2024 19:00:07 GMT

With ESMO 24 firmly in the rearview mirror, the dust settling, and the end of the year closing in, Michael and Josh take one final look at the trials that may change practice, direct research, or are just generally interesting. This week, we interviewed Dr Geoffrey Chong, a medical oncologist specialising in gastrointestinal cancers who currently holds appointments at the Olivia Newton-John Cancer Wellness and Research Centre and the Northern Hospital.

Enjoy!

Links to studies discussed in this episode (subscription may be required):

APOLLO

LEAP-012

CABINET

INTERAACT-2

MOONLIGHT

NICHE-2

NICHE-3

TOPGEAR

RAMTAS

SOLARIS

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

131. ESMO 2024 - Plenary Special

Wed, 18 Sep 2024 14:47:25 GMT

We have finally come to the end of ESMO 2024, and as is now tradition, Michael and Josh conclude their epic journey with a special episode highlighting their absolute favourite practice-changing selections from the Plenary Sessions. As always, ESMO brought a selection of wonderful studies that truly deserve the title "practice changing." As always, a huge thanks to everyone who joined us on this amazing journey. It has been a wonderful experience to attend a major international conference for the first time, and we are so privileged to be able to bring these results to you.

Stay tuned to Oncology for the Inquisitive Mind in the coming weeks as we will be starting our ESMO 2024: Retrospective miniseries, where we speak to experts in the areas of breast, lung, GI, GU and skin cancers and get their opinions on the goings on in Barcelona.

PEACE-3

PODIUM

KEYNOTE-A18

KEYNOTE-522 OS Data

NIAGARA

Note: this episode was recorded over two days at two separate locations.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

130. ESMO 2024 - Day 4

Tue, 17 Sep 2024 17:47:43 GMT

The end of the road approaches, and ESMO 2024 will soon be in the rearview mirror. However, each new day brings new, incredible advances in the treatment of cancer. Today, Josh and Michael dive into biomarker analyses, overall survival updates and new antibody-drug conjugates galore. Listen on for our penultimate summary of ESMO.

Studies discussed in this episode:

Biomarker analysis of PEACE-1

ARANOTE

STAMPEDE - Addition of Metformin

Clinical activity of BMS-986365, dual androgen receptor ligand-directed degrader and antagonist in heavily pretreated mCRPC

Nivo (3mg/kg) + ipi (1mg/kg) in molecularly-selected patients with mCRPC

Neoadjuvant nivo/rela or nivo/ipi in TNBC with high TILs

Adjuvant ribo + NSAI in patients with HR+/HER2- EBC: 4 year NATALEE

Cabozantinib vs placebo for advanced NET after progression on prior therapy (CABINET)

Osimertinib after definitive CRT: analysis of CNS and distant progression from LAURA

POTENTIAL

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

129. ESMO 2024 - Day 3

Mon, 16 Sep 2024 18:00:00 GMT

Day three of the European Society of Medical Oncology Congress had many exciting and potentially practice-changing trials in the genitourinary space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy.

They look at biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma.

Links to studies discussed in this episode (subscription may be required):

DV001 (Disitamab vedotin (DV) + pembrolizumab in treatment-naïve HER2-expressing LA/met UC)

EV-302 - nectin four expression

UpFrontPSMA Study

Splash Study (Lu-PNT2002)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Splash

Disitimab Vedotin

Hosted on Acast. See acast.com/privacy for more information.

128. ESMO 2024 - Day 2

Sun, 15 Sep 2024 21:11:34 GMT

Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the European Society of Medical Oncology. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supportive care to head and neck cancer and so many other fascinating studies in between. Read on to listen to the boys' best bits from Barcelona on Day 2 of ESMO.

Studies discussed in this episode:

Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)
Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)
TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study
Interim analysis of GALAXIES Lung-201: belrestotug + dostarlimab in 1L for PD-L1 TPS >/= 50% NSCLC
Ivonescimab +/- ligufalimab + FOLFOXIRI as 1L treatment for mCRC
Efficacy and safety of ribociclib + NSAI in younger patients with HR+/HER2- EBC (NATALEE)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

127. ESMO 2024 - Day 1

Sat, 14 Sep 2024 20:36:04 GMT

The European Society of Medical Oncology Congress has begun, and Michael and Josh are on the ground, bringing you breaking studies and heartbreaks along with some important updates in the science and art of medical oncology.

Michael and Josh cover a range of tumour types on day one, a slight deviation from our regular coverage. They look at hepatocellular carcinoma, renal cancers, and breast cancer, an eclectic but exciting mix of cancer types.

Michael investigates HCC treatment with iparomlimab and tuvonaralimab with bevacizumab in a first line setting, along with some updated efficacy from the IMbrave050 trial. He finishes off his whirlwind tour of day one summarising some interesting education points in the metastatic colorectal cancer space. Josh looks at Tivozanib-Nivolumab in advanced RCC following immunotherapy, along with another trial where Belzutifan may be another treatment option. He finishes up with HER3-directed therapy!

Links to studies discussed in this episode (subscription may be required):

Phs II/III DUBHE-H-308

Imbrave050 (HCC)

TiNivo-2 Study (mRCC)

Litespark 005 (mRCC)

Checkmate 8HW (mCRC)

Icarus-Breast 01 (mBreast Cancer)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

126. Ocular Melanoma and Prostate Cancer with A/Prof Anthony Joshua

Sat, 24 Aug 2024 20:00:23 GMT

Oncology for the Inquisitive Mind has been privileged to interview some truly brilliant specialists, and this week's guest is no exception. Professor Anthony Joshua is the Head of Oncology at the Kinghorn Cancer Centre and St Vincent's Health in Sydney. He is a globally recognised expert in genitourinary cancers and melanoma, with a special interest in ocular melanoma.

Professor Joshua completed his PhD in prostatic carcinogenesis under the supervision of Dr Jeremy Squire and a clinical fellowship under Dr Ian Tannock. He worked at Princess Margaret Cancer Centre before returning down under and has helped reshape cancer care at the Kinghorn Cancer Centre, making it one of the largest trial centres in New South Wales. Today, Professor Joshua discusses his journey, the landscape of prostate cancer, and some of his research in the area of ocular melanoma.

Professor Anthony Joshua is not a professional British boxer. To find out more about Professor Anthony Joshua's research portfolio, click here

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Spotify Link to Prof Joshua's podcast, Dangerous Ideas in Drug Development: https://podcasters.spotify.com/pod/show/necta

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

125. Spotlight - Biotech ImmVirX with Dr Malcolm McColl and Prof Darren Shafren

Sat, 17 Aug 2024 20:00:34 GMT

Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used in melanoma and other malignancies.

ImmVirx has developed a proprietary bio-selected RNA virus that is showing promising pre-clinical and phase 1 results as monotherapy in hard-to-treat cancers, including colorectal, gastric hepatocellular and ovarian cancers.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

124. Metastatic HER2- positive breast cancer

Sat, 10 Aug 2024 20:00:46 GMT

Metastatic HER2-positive breast cancer continues to dominate headlines, and new therapeutic options continue to be found for those afflicted with the disease. Before trastuzumab (anti-HER2 therapy), the overall survival for this cohort of patients was less than two years. As technology and treatments changed, it can boast an extended survival well beyond five years in numerous studies, with many patients responding far more than that number.

This week, we will discuss two exciting and pioneering studies. The first looks at tucatinib, a tyrosine kinase inhibitor with known results in those with intracranial disease. The second is the use of abemaciclib in hormone receptor-positive, HER2-positive breast cancer in patients previously treated with trastuzumab.

Links to studies discussed in this episode (subscription may be required):

HER2CLIMB: Link

monarcHER: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

123. Spotlight: MARIPOSA for EGFRmut Lung Cancer

Sat, 03 Aug 2024 20:00:15 GMT

The discovery of EGFR as a driver mutation and the development of medications to take advantage of this mutation changed the treatment of non-small cell lung cancer (NSCLC) forever. Not only did it vastly improve outcomes for patients with this subset of cancers, it opened the door for the likes of alectinib, lorlatinib and sotorasib to carve out niches for their own driver mutations. However, the treatment remains imperfect and people much smarter than Josh and Michael have been hard at work trying to improve on the current standard of care, osimertinib. This brings us to MARIPOSA, a study that combined the dual EGFR-MET bispecific antibody amivantamab with the CNS-penetrant anti-EGFR TKI lazertinib, and uniquely compared it to osimertinib. Will this combination dethrone the king and rule the roost in EGFRmut NSCLC? Or will excessive toxicity and logistical concerns consign it to a niche at best? Listen on to find out!

Links to studies discussed in this episode (subscription may be required):

MARIPOSA: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

122. Palliative Care with Dr Janet Abrahm

Sat, 27 Jul 2024 20:00:08 GMT

It is rare on any show to be able to interview a true pioneer. On today's episode of Oncology for the Inquisitive Mind, we have the privilege of interviewing Dr Janet Abrahm, a pioneer in every sense of the word. An internist with over 20 years experience, Dr Abrahm was one of the founders and earliest proponents of palliative care in the United States. A staff specialist at the Dana Farber Cancer Institute, she is board-certified in Hematology, Hospice and Palliative Medicine, Internal Medicine, and Oncology. She has lectured on palliative care in the DFCI Master Course for oncologists throughout the US. Since 2010 she has participated internationally in the Education in Palliative and End-of-Life (EPEC)-Oncology course as a Master teacher. Most recently, she was the recipient of the 2024 Walther Cancer Foundation Supportive Oncology Award, recognising a distinguished lecturer and leader with multiple, significant, and enduring contributions to palliative and supportive care in oncology through the prevention, assessment and management of cancer- and treatment-related suffering. Oncology for the Inquisitive Mind is truly privileged to have Dr Abrahm on the show.

For more information on Dr Abrahm, or to subscribe to her palliative care newsletter, visit: https://janetabrahm.com/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

121. Dr Elias Chandran, the NCI and Urothelial Caricinoma

Sat, 20 Jul 2024 20:00:08 GMT

This week, we interview Dr Elias Chandran, a medical oncologist and emerging research juggernaut who is an assistant research physician at the National Cancer Institute in Bethesda, Maryland. His focus is on genitourinary cancer, and he has recently published a pivotal systematic review and meta-analysis titled "Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis".

Dr Chandran is the epitome of a resilient clinician, having trained and worked in multiple countries and taking every opportunity granted to him. For any trainees or junior medical staff curious about oncology careers and how to make the most of your journey, Elias's story is one not to miss.

To find out more about Elias and his research, click here: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

120. Artificial Intelligence & Cancer with Professor Meredith Broussard

Sat, 13 Jul 2024 20:00:54 GMT

Today, Michael and Josh interview Professor Meredith Broussard to discuss Artificial Intelligence (AI), its role in cancer diagnosis, her journey with breast cancer and her inspiration for her latest book, More than a Glitch. Meredith is a data journalist at the Arthur L Carter Journalism Institute of New York University and has had an exceptionally versatile career, previously having worked as a software developer for MIT Media Lab and a former features editor at the Philadelphia Inquirer.

She is also the author of numerous other books, including Confronting Race, Gender, and Ability Bias in Tech and Artificial Unintelligence. She is the research director at the NYU Alliance for Public Interest Technology.

For further information on Meredith, please see the link below:

Professor Meredith Broussard

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

119. ASCO 2024 - Plenary Session

Mon, 17 Jun 2024 06:00:00 GMT

"Here at last, at the edge of the sea, comes the end of our Fellowship." So said Gandalf the White at the conclusion of J.R.R Tolkien's epic The Lord of the Rings. Today, Josh and Michael have a no less epic conclusion to their own adventure, that of ASCO 2024. Over the last fifteen days, our intrepid hosts have journeyed across the world of medical oncology, from the highs of colorectal, breast and lung cancer to the dark days of central nervous system tumours. As is our tradition, we end our coverage with a look at the studies chosen by the ASCO committee as worthy of special attention: the plenary presentations. It is rare indeed to have four presentations in one year that all change clinical practice, but that is what we have been treated to this year.

Thank you for joining us for coverage of ASCO 2024; we have enjoyed ourselves immensely in covering it, and we hope you have enjoyed our meandering journey through some of the best oncology researchers in the world. We will be back in a couple of weeks as Oncology for the Inquisitive arm returns to its normal programming.

Links to studies discussed in this episode (subscription may be required):

ESOPEC: Link

NADINA: Link

LAURA: Link

ADRIATIC: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

118. ASCO 2024 - Sarcoma

Sun, 16 Jun 2024 06:00:31 GMT

Today is the penultimate episode in our ASCO 2024 Odyssey. Michael and Josh have neglected sarcoma to date, but today is the day@ Sarcoma is rare, where clinician experience becomes paramount to treatment options and outcomes. They develop in soft tissues and bones and vary in origin, including deep soft tissue, bone, nerves, etc. Today, they explore three trials. The first is paclitaxel and avelumab in inoperable angiosarcoma, the second is perioperative radiotherapy with adjuvant immunotherapy in high-risk soft tissue sarcoma, and the final is a good old head-to-head trial of perioperative chemotherapy in soft tissue sarcoma (adriamycin plus ifosfamide vs gemcitabine and docetaxel.

Links to studies discussed in this episode (subscription may be required)

SU2C-SARCO32: Link

JCOG1306: Link

Phase II trial, multicenter, first-line paclitaxel-avelumab treatment for inoperable angiosarcoma: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

117. ASCO 2024 - Central Nervous System

Sat, 15 Jun 2024 06:00:00 GMT

Some consider the number 13 unlucky; fear of the number has its own name, "triskaidekaphobia." So it is perhaps somewhat fitting that day 13 of our ASCO Odyssey is dedicated to the cancer type with which scientists and doctors have had arguably the least luck in treating: central nervous system cancers. We still await CNS oncology's immunotherapy or EGFR/ALK moment, and unfortunately, as of ASCO 2024, that has not come yet. However, that has not stopped legions of incredibly dedicated and intelligent people from trying. ASCO 2024 brought us several very interesting studies, both in form and function, that we hope will lay the groundwork for that magical breakthrough in this very difficult group of cancers.

Links to studies discussed in this episode (subscription may be required)

A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas. Link

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. Link

N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Link

Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations. Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

116. ASCO 2024 - Early Lung Cancer & Mesothelioma

Fri, 14 Jun 2024 10:14:48 GMT

ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.

Links to studies discussed in this episode (subscription may be required):

BEAT-meso: Link

Checkmate 816 4 year update: Link

MIST5: Link

ctDNA-Lung-DETECT: Link

BEAT-SC: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

115. ASCO 2024 - Head and Neck Cancer

Thu, 13 Jun 2024 06:00:58 GMT

Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor prognosis and head and neck patients, and a new, intensive immunotherapy treatment for nasopharyngeal cancer. A wide variety of studies that are sure to satisfy a broad range of palates!

Links to studies discussed in this episode (subscription may be required):

TARGET-HPV: Link

Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status: Link

KCSG HN18-07: Link

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial: LinkFor more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

114. ASCO 2024 - Early Colorectal Cancer

Wed, 12 Jun 2024 06:00:23 GMT

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal contingent is the TNTCRT trial, looking at total neoadjuvant therapy vs concurrent chemoradiotherapy. While the world may have moved forward, this trial could provide further evidence of the path we should be taking.

Links to studies discussed in this episode (subscription may be required)

NEOPRISM-CRC: Link

TNTCRC: Link

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labelled, phase Ib study: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

113. ASCO 2024 - Metastatic Colorectal Cancer

Tue, 11 Jun 2024 06:00:50 GMT

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this episode, Josh and Michael examine studies looking at KRAS G12C-mutated, HER2-positive and dMMR colorectal cancer, as well as a very exciting study examining the utility of transplantation in patients with liver-only colorectal metastases.

Links to studies discussed in this episode (subscription may be required):

CODEBREAK300: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=234200%23234200

MOUNTAINEER: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=231646%23231646

CHECKMATE 8HW: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231645%23231645

TRANSMET: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231641%23231641

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

112. ASCO 2024 - Upper Gastrointestinal and Hepatobiliary Cancers

Mon, 10 Jun 2024 12:36:06 GMT

Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers. Like the eponymous lead of the 1992 classic Aladdin, several diamonds lie in the rough.

We cover perioperative FLOT in the metastatic setting, but most excitingly, it is a potentially new groundbreaking treatment for hepatocellular carcinoma.

Links to studies discussed in this episode (subscription may be required)

ECOG-ACRIN EA2174: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

ROTG 0848: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

CHECKMATE 9DW: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

RENAISSANCE: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

111. ASCO 2024 - Genitourinary Cancers (Prostate/Penile)

Sun, 09 Jun 2024 06:00:39 GMT

The second of our two GU ASCO 2024 episodes focusses on prostate and penile cancer, two diseases at different ends of the therapeutic spectrum. Prostate cancer is one of the most common cancers in men, with well established, nuanced treatment paradigms and a glut of high-quality evidence. Penile SCC is a very rare cancer that tragically is much more common in low socioeconomic countries. Treatment options are as limited as available evidence, so any new studies of this cancer are very welcome. Are there any more practice changing twists and turns from ASCO 2024? You'll have to listen to find out!

Links to studies discussed in this episode (subscription may be required)

Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153): Link

CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer: Link

A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study: Link

A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

110. ASCO 2024 - Genitourinary Cancers (Bladder/Kidney)

Sat, 08 Jun 2024 06:00:34 GMT

Genitourinary Cancers dominated ASCO24 this year, and Josh and Michael's ASCO Odyssey needed two episodes to fit it all in. Join them as they board the Nautilus with Captain Nemo in search of the best trials to propel bladder and renal cancer to the forefront of your mind. This episode covers both the use of perioperative sacituzumab govitecan, avelumab as neoadjuvant therapy for bladder cancer and camrelizumab for previously treated advanced adrenocortical carcinoma. Not to be forgotten, they explore a biomarker analysis of the CLEAR trial to see whether any treasure is to be found...

Links to studies discussed in this episode (subscription may be required)

SURE 01/02: Link

AURA: Link

CLEAR biomarker analysis: Link

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

The Star Spangled Banner courtesy of Music_Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

109. ASCO 2024 - Early Breast Cancer

Fri, 07 Jun 2024 06:00:07 GMT

Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examine four very interesting studies, looking at alternative immunotherapy strategies with adjuvant avelumab, adjuvant endocrine therapy omission in low-ER positive disease, ctDNA in predicting disease recurrence, and a study that aims to change the very bedrock of breast cancer classification. Lots to discuss, deconstruct and debate on today's episode!

Links to studies discussed (subscription may be required):

A-BRAVE: Link

Adjuvant ET omission in ER-low patients: Link

Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC): Link

Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

108. ASCO 2024 - Metastatic Breast Cancer

Thu, 06 Jun 2024 06:45:02 GMT

Today, Michael and Josh approach a singular destiny to present their take on Metastatic Breast Cancer at ASCO 2024. Long has Breast Cancer been one of the most diagnosed cancers globally; these days, it leads the herd with effective treatment options and paradigm shifts that benefit millions of people on a massive scale. With CDK4/6 inhibitors, immunotherapy and antibody-drug conjugates, the arsenal of effective treatment tools continues to grow! Nothing excites an oncologist more than a good randomised phase 3 international study. Today, they present the following:

Links to studies discussed (subscription may be required):

Destiny-Breast06: Link

postMONARCH: Link

INAVO120: Link

OptiTROP-Breast01: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

107. ASCO 2024 - Gynaecological Cancer

Wed, 05 Jun 2024 10:00:00 GMT

Day 3 of Oncology for the Inquisitive Mind's ASCO Odyssey and our hosts show no sign of flagging under this immense pressure, although Josh has started to give up on his famous segues. In this episode, our intrepid hosts tackle gynaecological cancers, reporting on four of their favourite studies from a packed field of gynaecological cancers. Will new treatment options for cervical cancer emerge? Will the sugical approach to recurrent ovarian cancer change? Is there still a place for single agent olaparib in the management of ovarian cancers? Listen on to find out.

Links to studies discussed in this episode (subscription may be required):

Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study: Link

AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer: Link

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial: Link

Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

The Star Spangled Banner courtesy of Music_Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

106. ASCO 2024 - Melanoma

Tue, 04 Jun 2024 06:00:42 GMT

As the sun rises on another day at ASCO, Michael and Josh are ready to hit the ground running to bring you the latest and greatest in all things oncology in Chicago has to offer. No greek mythology today, only a burning desire to bring you the biggest melanoma trials from ASCO24. Today, they pack a punch, tackling some intriguing phase 1 trials with tongue-twisting names where the novelty wears off pretty quickly!

Links to articles discussed in this episode (subscription may be required):

RELATIVITY-048: link

SX-682: link

PIVOTAL: link

BRENETAFUSP: link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

105. ASCO 2024 - Metastatic Non Small Cell Lung Cancer

Mon, 03 Jun 2024 09:00:28 GMT

"Tell me, Muse, the story of that resourceful man who was driven to wander far and wide after he had sacked Troy. He saw the cities of many people and he learnt their ways. Tell us this story, goddess daughter of Zeus, beginning at whatever point you will." So begins Homer's epic The Odyssey, the story of the titular hero Odysseus' long, long, LONG journey from the ruins of Troy to his home of Ithaca. Just as Odysseus set out from Troy, so do Michael and Josh begin an "odyssey" of their own. The American Society of Clinical Oncology's 2024 meeting is in full swing, bringing a veritable Charybdis of content into the world of medical oncology. The starting point for this epic journey is updates to non-small cell lung cancer, including a new contender for our hosts' favourite study of all time.

Links to articles discussed in this episode (subscription may be required):

EVOKE-1: Link

ICARUS-LUNG01: Link

CROWN 5-year update: Link

HARMONI-A: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

The Star Spangled Banner courtesy of Music_Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

104. Metastatic Gastric and GOJ Cancer

Sat, 01 Jun 2024 20:00:29 GMT

With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric cancer is 6%, similar to that of pancreatic cancer. Despite improvement in survival due to the addition of nivolumab to chemotherapy (Checkmate 64), few therapies have significantly changed it's overall prognosis.

This week Michael and Josh explore the addition of a LAG-3 inhibitor (relatlimab) to the SOC nivolumab and chemotherapy to see if gastric cancers fortune may change. Synergistic evidence has been seen in melanoma, but melanoma has a completely different biology.. Michael engages with Keynote-811, the addition of trastuzumab to SOC chemotherapy for hER2 positive metastatic gastric/GOJ cancer. Is this HER2 antibody strong enough to stop this cancers march?

Tune in today, and for the forseeable future and Josh and Michael go where no podcaster has gone before--->

Links to articles discussed in this episode (subscription may be required):

Relativity 060: Link

Keynote 811: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

103. Metastatic Colorectal Cancer

Sat, 25 May 2024 20:00:59 GMT

Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease course. This week, we look for the "SUNLIGHT" and investigate the combination of Lonsurf with Bevacizumab and using Fruquintinib with refractory metastatic colorectal cancer.

Links to articles discussed in this episode (subscription may be required):

FRESCO-2: Link

SUNLIGHT: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

102. Hepatocellular Carcinoma

Sat, 18 May 2024 20:00:23 GMT

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.

This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib (tyrosine kinase inhibitor). Will immunotherapy take the reigns as the preferred agents? Our second study is Compassion-08, (Michael has an abundance of this). The trial is unique as it involves a first-in-class bispecific antibody targeting PD-1 and CTLA-4 (cadonilimab in combination with lenvatinib).

Interesting times ahead in the HCC space

Links to articles discussed in this episode (subscription may be required):

HIMALAYA: Link

COMPASSION-08: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncosnacks 14: Bevacizumab Toxicity (Part 1)

Tue, 14 May 2024 20:00:40 GMT

In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes toxicity. Side effects related to bevacizumab are not your garden-variety chemotherapy side effects, nor are they similar to toxicity from immunotherapy. Rather, they stand apart, unique amongst our systemic therapies.

In their latest Onconack, Josh and Michael take a look at two of the most commonly described toxicities related to bevacizumab: hypertension and proteinuria. This is sure to be a valuable resource to any oncology trainee blessed (or cursed) with the unit pager!

Links to useful sources for further reading (subscription may be required):

Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials: Link

Practical Management of Bevacizumab-Related Toxicities in Glioblastoma: Link

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. Link

Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

101. Castration-Resistant Prostate Cancer Update

Sat, 11 May 2024 20:00:23 GMT

As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the latest oncology evidence to anyone with ears and the will to listen. Now, for episode number 101, Josh and Michael return to where it all started: prostate cancer. Much has changed in the (nearly) two years since that episode, and so in this episode, our hosts provide an update on two more recent updates in the prostate cancer space: Michael discusses TALAPRO-2, the latest in a flurry of studies examining patients with homologous-repair-deficient prostate cancer examining enzalutamide and talazoparib. Josh presents a study close to his heart; ENZA-P is an Australian-led study combining novel anti-androgen agents with the even-more-novel radioactive agent Lutetium-PSMA. Both represent the crest of the new wave of targeted prostate cancer treatment, and there are many tidbits to be gobbled up in this, the start of a new 100 episode cycle for Oncology for the Inquisitive Mind!

Links to articles discussed in this episode (subscription may be required):

TALAPRO-2: https://www.nature.com/articles/s41591-023-02704-x

ENZA-P: https://www.sciencedirect.com/science/article/pii/S1470204524001359?dgcid=coauthor

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

100. 100th Episode Bonanza

Sat, 04 May 2024 20:00:32 GMT

For 100 episodes, Josh and Michael have brought to your ears the latest and greatest in oncology research and treatment. In this episode, we will take a trip down memory lane, speaking about our journey up to this point, our favourite guests and favourite trials, and give you a glimpse of what the future holds for Oncology for the Inquisitive Mind. If we're honest, we never expected to get this far, and we have you, our wonderful audience to thank for that. We are so grateful for your support, you are the reason we keep coming back every week to record, and we hope to continue to bring you more oncology-related goodness for many more episodes to come!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

99. Early Mutation-Driver Positive NSCLC

Sat, 27 Apr 2024 20:00:18 GMT

In this episode, Josh and Michael examine the rapidly developing world of early lung cancer treatment. An area that will hopefully only grow in importance, treatment for early NSCLC is becoming ever more sophisticated, with recent developments in neoadjuvant management and confirmation of the benefit of adjuvant driver-mutation inhibitior treatment. Today's articles cover two such topics: will osimertinib finally reach the pinnacle it was born to reach and be used in the neoadjuvant treatment of EGFR-mutant NSCLC? Will alectinib join its older, more successful cousin in being effective in resected ALK-mutant NSCLC? Listen on to find out, but we'll give you this one for free: if you have a patient with early NSCLC, it is becoming imperative that you test them for these mutations. Truly a fascinating time.

Links to articles discussed in this episode (subscription may be required):

NEOS: https://www.lungcancerjournal.info/article/S0169-5002(23)00072-7/fulltext

ALINA: https://www.nejm.org/doi/full/10.1056/NEJMoa2310532

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

98. Breast Cancer with Dr Adam Brufsky

Sat, 20 Apr 2024 20:00:48 GMT

On this very special episode, Josh and Michael welcome Dr Adam Brufsky, a trailblazer in the world of breast cancer treatment and a titan in the frenetic development of breast cancer therapies since the mid-late 90s. Dr Brufsky is a Professor of Medicine at the University of Pittsburgh School of Medicine, Chief of the university's Division of Haematology and Oncology and co-director of its Comprehensive Cancer Centre. He received his MD and PhD from the University of Connecticut's School of Medicine in 1990 and has previously worked at Bringham and Women's Hospital and the Dana-Farber Cancer Institute. His areas of special interest include novel therapeutics and management strategies for breast cancer, bone-breast cancer interactions and therapeutics and molecular biology of metastatic breast cancer. He is a font of knowledge and we are so privileged to welcome Dr Brufsky onto the show.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Fireside Chats 3: Colorectal Cancer in Young People

Sat, 13 Apr 2024 20:00:23 GMT

On today's blessedly brief episode, Josh and Michael give an overview of one of the greatest challenges for any practicing oncologist: the conundrum of cancer in young people. In recent decades, the number and proportion of young patients diagnosed with colorectal cancer has skyrocketed. This trend has been noted in news outlets across the world, reported in sources as disparate as the New York Times and the Australian Broadcasting Company. From the medical to the logistical and emotional, managing a young person with a cancer diagnosis is very difficult. While neither of our intrepid hosts has an answer to this very complex topic, there are a number of nuggets they drop that could help. Listen on for a thought provoking episode of Oncology for the Inquisitive Mind.

Article discussed in this episode (subscription may be required):

"‘More Young People Than Ever Will Get Colorectal Cancer This Year," by Knuvul Sheikh.

Available from: https://www.nytimes.com/2024/03/27/well/colon-cancer-symptoms-treatment.html?unlocked_article_code=1.gE0.C_DO.__AnqnMB1F4M&smid=nytcore-ios-share&referringSource=articleShare

Art courtesy of Taryn Silver

Audio courtesy of:

Olexy on pixabay: https://pixabay.com/users/olexy-25300778/
JuliusH on pixabay: https://pixabay.com/users/juliush-3921568/

The opinions discussed in this episode are those of the authors and should not be taken for medical advice. They exist to engender discussion, debate and thought.

Hosted on Acast. See acast.com/privacy for more information.

Oncosnacks 13: Pancreatic Cancer - NAPOLI-3 Trial Update

Tue, 09 Apr 2024 20:00:02 GMT

IN BREAKING NEWS... Or not really, as we are a bit late to the party. But in honour of liposomal irinotecan's recent approval by the Federal Drugs Administration, we thought we would take another look at the NAPOLI-3 trial. The first potentially practice-changing update to the treatment of advanced pancreatic cancer arguably in more than a decade, the combination of liposomal irinotecan with 5-fluorouracil and oxaliplatin proved itself superior (spoiler alert) to the established combination of gemcitabine and nab-paclitaxel. Will this practically change practice for our patients? The answer, for Australia at least, is a resounding maybe. Listen on for all the juicy details, and the return of OftiM Newsreader "Walter Fernando-Cronkite."

Links to articles discussed in this episode (subscription may be required):

NAPOLI-3: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01366-1/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

97. Spotlight: Advanced Breast Cancer - Which CDK4/6 Inhibitor is Best?

Sat, 06 Apr 2024 20:00:54 GMT

It is a tale as old as time, as old as the stars, the heavens and human consciousness itself. Okay, we're exaggerating a bit, but for as long as pharmacology and capitalism have been joined at the hip, the question of "which drug is best" has been at or near the forefront of medical decision-making. With the development of standardised clinical trials and the difficulty of conducting direct head-to-head comparisons, this question has become more difficult to answer conclusively. Nowhere is this epitomised better than with the triptych of available CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib. A lot of ink and pixels have been devoted to comparing the pivotal trials of these three equally pivotal agents: PALOMA-2, MONALEESA-2 and MONARCH-3, respectively. However, Josh and Michael have brought the definitive and not-at-all rambling answer to this question. Listen on to find out!

Links to studies discussed in this episode (subscription may be required):

Review Article (Grinshpun et al.): https://www.nature.com/articles/s41523-023-00520-7

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

96. Second Line Treatment of Melanoma

Sat, 30 Mar 2024 19:00:43 GMT

In this episode, Michael and Josh welcome a very special guest: Michael's Labrador Beans. Beans is a world-renowned expert in eating snacks, but unfortunately, had very little to offer on their topic today: the treatment of progressive or recurrent cutaneous melanoma with primary and secondary resistance to immunotherapy. So, unfortunately, the discussion was left to your regular hosts.

For approximately 50% of patients, this is fortunately not a question they need to worry about, as immunotherapy and BRAF/MEK inhibitors remain effective treatments. However, that still leaves half of all patients facing an uncertain future, as treatment beyond these two agents remains uncertain. Josh and Michael examine two studies that may shine a light in this dark corner of oncology: LEAP-004, a single-arm study of lenvatinib + pembrolizumab, and an article published in the New England Journal of Medicine examining the use of tumour-infiltrating lymphocytes (TILs) as a novel weapon against immunotherapy-resistant melanoma.

Links to studies discussed in this episode (subscription may be required):

LEAP-004: https://ascopubs.org/doi/full/10.1200/JCO.22.00221

Rohaan et al: https://www.nejm.org/doi/full/10.1056/NEJMoa2210233

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

95. ASCO GU 2024 Spectacular (Part 2)

Sat, 23 Mar 2024 19:00:56 GMT

While Josh and Michael enjoy a good rambling, meandering podcast as much as the next guy, we made a promise to keep our coverage of the ASCO GU 2024 conference short and sweet. So, as promised, here is the second - and final - episode of our miniseries. For a change of pace, one of our studies involves the adjuvant use of immunotherapy! Specifically, AMBASSADOR looks at pembrolizumab in patients with early urothelial cancer, a patient cohort that is crying out for more effective treatments for early-stage disease. Meanwhile, Josh tries to "BRCAAway" from our comfort zone by discussing the latest trial examining the use of PARP inhibitors in metastatic castration-resistant prostate cancer. Yes, we'll show ourselves out now.

Links to studies discussed in this episode (subscription may be required):

AMBASSADOR (courtesy of ASCO Daily news): https://ascopost.com/news/january-2024/ambassador-pembrolizumab-in-muscle-invasive-and-locally-advanced-urothelial-carcinoma/#:~:text=AMBASSADOR%20(A031501)%20is%20a%20randomized,and%20locally%20advanced%20urothelial%20carcinoma.

BRCAAway (courtesy of urotoday.com): https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137781-asco-2022-brcaaway-a-randomized-phase-2-trial-of-abiraterone-olaparib-or-abiraterone-olaparib-in-patients-with-mcrpc-with-dna-repair-defects.html

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

94. ASCO GU 2024 Spectacular (Part 1)

Sat, 16 Mar 2024 19:00:46 GMT

With Josh's Grand Adventure(TM) now in the books, he and Michael return to their usual programming, examining two studies presented at the not-so-recent ASCO GU conference in San Fransisco. While the conference took place in January of this year, as the old adage goes: better late than never. In this episode, our hosts examine two studies; the CONTACT-02 study examining a combination of immunotherapy + cabozantinib in patients with metastatic castration-resistant prostate cancer, and an update from the KEYNOTE-564 that examined whether pembrolizumab had any benefit in the adjuvant treatment of renal cell cancer. Will either of these studies change practice? Fear not, for our fearless oncological explorers are on hand to guide you through the hazardous ratios and nefarious p values!

Links to studies discussed in this episode via ASCO Daily News(subscription may be required):

CONTACT-02: https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.18#:~:text=CONTACT%2D02%20is%20the%20only,Clinical%20trial%20information%3A%20NCT04446117.

KEYNOTE-564: https://dailynews.ascopubs.org/do/keynote-564-adjuvant-pembrolizumab-prolongs-survival-high-risk-clear-cell-renal-cell#:~:text=KEYNOTE%2D564%20is%20the%20first,at%20higher%20risk%20for%20recurrence.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

93. On the Road with Prof. Elgene Lim

Sat, 09 Mar 2024 19:00:51 GMT

In this episode, Josh interviews the man who helped make this grand adventure possible, his mentor, Professor Elgene Lim of the Kinghorn Cancer Centre in Sydney. Professor Lim is a medical oncologist specialising in breast cancer research. He has previously worked at the Walter and Eliza Hall Institute, completing his PhD under the mentorship of Dr Geoffrey Lindeman and Dr Jane Visvader with research focussed on identifying culprit cells in BRCA1 mutant gene carriers. He subsequently worked with Dr Eric Winer and Dr Myles Brown at the Dana-Farber Cancer Institute and Harvard Medical School. As if this was not enough, Elgene is proud of his volunteer work with asylum seekers and his work with the Asha Kiran Hospital in Orissa, India, in a program of expertise transfer and partnership with local doctors.

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

92. On the Road with Dr. Robert Mayer

Sat, 02 Mar 2024 19:00:41 GMT

In this episode, Josh interviews Dr Robert Mayer, Professor of Medicine at Harvard Medical School, former director of the Dana Farber Cancer Institute’s Oncology Fellowship Program for 36 years and an expert in gastrointestinal cancer. He founded the Centre for Gastrointestinal Oncology at Dana Farber and has previously chaired the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B. Dr Mayer has also been an associate editor for both the New England Journal of Medicine and the Journal of Clinical Oncology and is a former ASCO president. Bob is the recipient of ASCO’s Distinguished Achievement Award in 2019 and as Josh likes to remind me, a living legend.

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

91. On the Road with Dr. Ann Partridge

Sat, 24 Feb 2024 19:00:02 GMT

In this episode, Josh interviewed Dr Ann Partridge, the director of the adult survivorship program at the Dana-Farber Institute. She is the co-founder and director of the Program for Young Women with Breast Cancer and is passionate about communication, risk perception and behavioural aspects of cancer care. Dr Partridge is the principal investigator for the Young Women’s Breast Cancer study, which has currently enrolled over 1300 women throughout the United States, and has chaired both ASCO’s scientific program committee and the ESMO-sponsored Breast Cancer in Young Women Conference. In 2018, Dr Partridge was recognized with the American Association for Cancer Research's Outstanding Investigator Award for Breast Cancer Research.

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

90. On the Road with Dr. Harold J Burstein

Sat, 17 Feb 2024 19:00:26 GMT

In this episode, Josh interviews Dr Harold Burstein. A graduate of Harvard University and Harvard Medical School, Dr Burstein’s initial PhD was in cellular immunology. After receiving his oncology fellowship at the Dana Farber Cancer Institute, he joined the staff in 1999. Hal has a particular interest in breast cancer and has participated in national and international clinical trials while also working to develop treatment guidelines worldwide. A passionate educator, Dr. Burstein teaches medical students, residents and fellows at Harvard Medical School and the Dana Farber Cancer Institute.

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

89. Spotlight - Biotech: Interview with Dr Jeff Jones from Cullinan Oncology

Tue, 13 Feb 2024 19:00:23 GMT

Today, on this mid-week special, Oncology for the Inquisitive Mind is delighted to welcome Dr. Jeff Jones, a haematologist, oncologist and the Chief Medical Officer of Cullinan Oncology. Biotech companies are at the forefront of novel drug development, and it is fascinating to take a look behind the curtain and glimpse a small part of how targets are chosen and developed. This includes areas of unmet need, including Exon 20 EGFR mutant lung cancer treatment.

Cullinan Oncology conducts research focused on immuno-oncology and translational cancer medicine, specifically focusing on small molecules and biologics to identify unique targets and develop transformative therapeutics across cancer indications.

Many thanks to Dr Jones and the team at Cullinan for taking the time to appear on our show.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

88. On the Road with Dr. Geoffrey Shapiro

Sat, 10 Feb 2024 19:00:42 GMT

We return to the Dana Farber Cancer Institute this week as part of our "On the Road" series and interview the multitalented Dr. Geoffrey Shapiro. Dr Shapiro completed his medical training at Cornell University and received his PhD in 1987. His passions lie in early-phase drug development and clinical trials, with a specific flair for cell cycle and DNA repair inhibitor therapeutics. Dr. Shapiro provides an insightful take on drug development, current opportunities, challenges, the world of CDK inhibitors and the future landscape of trials, along with the role of Project Optimus (no, not Optimus Prime!)

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

87. On the Road with Dr. Eric Winer

Sat, 03 Feb 2024 19:00:17 GMT

Today, we interview Dr. Eric Winer, our second guest in our mini-series "On the Road". Dr Winer is no ordinary Oncologist; he is a prolific clinician and researcher, despite being born with haemophilia and living with the consequences of early treatment for this, including HIV. In this episode, OFTIM explores his formative years, challenges and triumphs as he provides unique insights as both a patient and a clinician. This episode was recorded live in front of a captive audience in Sydney, Australia.

Eric is a decorated oncologist who graduated from Yale University School of Medicine and is currently the director of Yale Cancer Centre. He has held many prestigious positions, including the Chair of the American Society of Clinical Oncology and the Chief of the Breast Oncology Program at Dana-Farber Cancer Institute.

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

86. On the Road with Dr. Erica Mayer

Sat, 27 Jan 2024 19:00:26 GMT

Today, we interview Dr. Erica Mayer as our first guest in the "On the Road" mini-series. Dr. Mayer is a renowned breast cancer oncologist at the Dana Farber Cancer Institute. Each week for the next seven weeks, Michael and Josh will introduce a new guest to share their wealth of experience, expertise and wisdom, covering all the essential topics from career development, mentorship and necessary trials and challenges in the oncology world.

Dr. Mayer graduated from Harvard Medical School and completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Erica is the Director of Breast Cancer Clinical Research and is involved in multiple trials, which she discusses in this interview, along with the role of the PACE trial, CDK 4/6 inhibitors, CT DNA and many other important facets of the breast cancer world.

The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.

The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.

Hosted on Acast. See acast.com/privacy for more information.

85. Spotlight: Year in Retrospect: 2023

Sat, 20 Jan 2024 19:00:31 GMT

Oncology for the Inquisitive Mind is back, and we have a blockbuster year ahead! Before we get there, we have our year in review 2023. Michael and Josh have poured over the treasure trove of pivotal trials from 2023 to bring you the best studies (in our opinion) from the last 365 days! We used various complex metrics involving no science or maths at all.

Just when you thought you were free from oncology learning, we drag you back in, much like Al Pacino's character from The Godfather is famously quoted saying, "Just when I thought I was out, they pull me back in!". We hope you all have a great year ahead!

Links to studies discussed in this episode (subscription may be required):

5 Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

4 FLAURA2

3 INDIGO

2 MONARCH-E

1 EV-302/KEYNOTE-A39

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

84. World Conference on Lung Cancer (part 2)

Sat, 30 Dec 2023 19:00:27 GMT

2023 has been a year of highs and lows, a calendar of peaks and troughs, an epoch of mountains and valleys (all right Michael, put the thesaurus away...). From standing ovations for enfortumab vedotin and vorasidenib, to the ongoing black hole that is effective treatments for pancreatic and hepatocellular carcinomas. However, through it all the brightest minds in the field have continued to stoke the fires of hope with the development of novel antibody-drug conjugates, immunotherapies and clever applications of established treatments.

How fitting, then, that Josh and MIchael - definitely NOT amongst the brightest minds in the field, but two of the most enthusiastic - end their coverage of 2023 with a final glance into the future of lung cancer treatment. Keeping themselves to a (not so) strict five minute limit, they will look at four studies that may offer a glimpse into how lung cancer of both the small- and non-small cell variety may be managed.

We wish you a very happy and safe New Year, and a happy beginning to 2024.

Links to studies discussed in this episode (subscription may be required):

DS-7300: https://meetingsapp.iaslc.org/event/wclc2023/planning/UGxhbm5pbmdfMTUyNDQwMw==

ETER701: https://meetingsapp.iaslc.org/event/wclc2023/planning/UGxhbm5pbmdfMTUyNDgwNQ==

INTELLECT: https://pubmed.ncbi.nlm.nih.gov/36829154/

HERTHENA-Lung01: https://ascopubs.org/doi/full/10.1200/JCO.23.01476

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Additional sound effects courtesy of Pixabay: https://pixabay.com/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

83. World Conference on Lung Cancer (part 1)

Sat, 23 Dec 2023 12:00:50 GMT

ASCO and ESMO are done, and soon, 2023 itself will be in the rearview mirror. And yet, there are still conferences happening around the world; yes, we know the World Conference on Lung Cancer occurred before ESMO, but there is such a thing as too much of a good thing. Join Michael and Josh on their latest virtual journey abroad, this time to the equatorial island of Singapore, as they report on two of their favourite studies from WCLC 2023. For those who celebrate, have a Merry Christmas and a happy festive season.

Links to studies discussed in this episode (subscription may be required):

MARS-2: https://pubmed.ncbi.nlm.nih.gov/32873681/

FLAURA2: https://www.nejm.org/doi/full/10.1056/NEJMoa2306434

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncosnacks 12: Enfortumab Vedotin skin toxicity management

Tue, 19 Dec 2023 19:00:51 GMT

On this episode, their final of 2023, Michael and Josh return to the world of recent fan favourite, enfortumab vedotin (EV). Not content to sing its praises from every rooftop, our intrepid hosts take the necessary step of examining the common and sometimes severe manifestations of dermatological toxicity deriving from EV. With the assistance of a recently published guideline, they examine the presentation, assessment and management of skin toxicity.

From all of us at OftiM, we would like to thank you for joining us throughout 2023, and we wish you a very happy festive season.

Useful Links:

Guideline ( et al, 2023): https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.19454

CTCAE 5.0 guidelines for skin toxicity: https://www.researchgate.net/figure/Folliculitis-example-of-an-existing-toxicity-in-CTCAE_fig3_323714281

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

82. Metastatic triple negative breast cancer (TNBC)

Sat, 16 Dec 2023 12:00:47 GMT

Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space. However, the fight of the world's oncologists continues across all fronts, and TNBC is no different. In today's episode, Michael and Josh will discuss the twin pillars of modern anti-cancer therapies: antibody-drug conjugates (sacituzumab govitecan) and immunotherapy (pembrolizumab). As so often the case, this is a growth area of medical oncology and one that we are very excited to (finally) address.

Links to studies discussed in this episode (subscription may be required):

ASCENT: https://www.nejm.org/doi/full/10.1056/NEJMoa2028485
KEYNOTE-355: https://www.nejm.org/doi/full/10.1056/NEJMoa2202809

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Fireside Chats 2. Time Toxicity in Early Phase Trials

Tue, 12 Dec 2023 19:00:08 GMT

For patients with advanced cancer, early-phase trials may represent the last best hope of significant anticancer response. For clinicians, every early phase trial holds virtually unlimited promise and hope of becoming the next immunotherapy or hot antibody-drug conjugate. However, early-phase trials also come with significant uncertainty of efficacy, toxicity and even dosing.

A recent Limbic article (link below) reported on an article published in ESMO Open that investigated the burden of "time toxicity" for patients enrolled in early-phase clinical trials, and advocated for this to be minimised. While it is essential to consider logistic factors and patient preferences, early-phase trials are frequently more inflexible compared to phase II or III studies, and are constructed as such to ensure patient safety in the face of significant unknowns.

In this episode of Fireside Chats, Michael and Josh discuss the pros and cons of attempting to streamline early phase trials, if it is possible, and what can be done to minimise a trial's impact on a patient's day-to-day and quality of life.

Article discussed in this episode (subscription may be required):

"‘Time toxicity’ burden for patients in early phase cancer trials," by Siobhan Calafiore

Available from: https://thelimbic.com/oncology/time-toxicity-burden-for-patients-in-early-phase-cancer-trials/?utm_source=sfmc&utm_medium=email&utm_campaign=Onc%201.12.23&utm_term=Read%20more&utm_id=91262&uid=12231&lk=0d144a028ccc3d800f567af6e9fa7662

Art courtesy of Taryn Silver

Audio courtesy of:

Olexy on pixabay: https://pixabay.com/users/olexy-25300778/
JuliusH on pixabay: https://pixabay.com/users/juliush-3921568/

The opinions discussed in this episode are those of the authors and should not be taken for medical advice. They exist to engender discussion, debate and thought.

Hosted on Acast. See acast.com/privacy for more information.

81. San Antonio Breast Cancer Symposium Update

Sat, 09 Dec 2023 12:00:57 GMT

San Antonio Breast Cancer Symposium is here, and this year, OFTIM (Oncology for the Inquisitive Mind) is bringing you the latest and greatest in all things breast cancer. With over 10000 attendees, the research and vibrant discussions did not disappoint, with updates, controversies and complexities. Taking centre stage were PIK3CA mutation treatments, updates on CDK4/6 inhibitors and the age-old question - does exercise improve outcomes for our patients?

Studies discussed in today's episode (subscription may be required)

MONARCH-3
KATHERINE
INAVO120
PREFERABLE EFFECT

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

80. ESMO 2023 - Plenary Session

Tue, 07 Nov 2023 20:00:05 GMT

Today, OFTIM celebrates its 80th episode and presents its ESMO23 plenary session, including two practice-changing, paradigm-shifting trials. The first investigates the EGFR mutation Non-Small Cell Lung Cancer world with new drugs (amivantamab and lazertinib) to treat patients hose who progressed on osimertinib. The second trial is the EV-302/KEYNOTE-A39, which explores whether enfortumab vedotin (ADC) and pembrolizumab (immunotherapy) can best-platinum-based chemotherapy. No prior trial has ever done this, so the stakes are high. As the little engine once said, "I think I can", and, we, too, continue to see seismic shifts in cancer treatment in our quest for better therapy.

For now, the OFTIM team is signing out and taking a small break after daily reporting, but we hope you loved it and can't wait to return with more from the fascinating world of Medical Oncology.

Studies

EV-302/KEYNOTE-A39 - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639614

MARIPOSA-2 - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639283

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

79. ESMO 2023 - Gynaecological Oncology

Mon, 06 Nov 2023 19:00:12 GMT

As Oncology for the Inquisitive Mind's coverage of ESMO 2023 winds down, we bring some of the best presentations covering gynaecological cancer. An area of oncology that in many cases remains mired in the pre-immunotherapy and pre-targeted therapy ages, ESMO brought some much-needed positive trials in the areas of cervical cancer, as well as an interesting (albeit negative) study of the PARP-inhibitor olaparib that highlights some of the more practical challenges of running an international phase 3 study. As always, outcomes can always improve, but any progress in this very important area is always a welcome development.

Studies discussed in this episode (subscription may be required):

A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639091
innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639430
Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639154

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

78. ESMO 2023 - Skin Cancer and Melanoma

Sun, 05 Nov 2023 19:00:47 GMT

Since the early development of immunotherapy, metastatic melanoma has been the golden child of medical oncology. In recent years, similar outcomes have been seen with immunotherapy in non-melanomatous skin cancers. Cemiplimab is now a standard of care for patients with locally advanced, unresectable or metastatic cSCC, and is particularly effective in patients with cancer driven by UV-induced DNA damage. However, oncologists and researchers are always looking for new and better ways to use established treatments. At ESMO 2023 two papers took this approach; one examined moving immunotherapy to the neoadjuvant space, while another added a venerable EGFR inhibitor to treatment of advanced cSCC. However, the undoubted star of this show is the long-term results of tebentafusp, the first efficacious treatment of a subtype of the notorious uveal melanoma. ESMO 2023 truly had something for everyone, and the melanoma and skin cancer areas were no exception.

Studies discussed in today's episode (subscription may be required)

A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up. https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638272
Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639251
A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638271

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

77. ESMO 2023 - Non Small Cell Lung Cancer

Thu, 02 Nov 2023 19:00:48 GMT

Non-small cell lung cancer continues to show massive promise with new trials, better designs and exciting utilisation of existing therapies. Michael and Josh explore immunotherapy in a "sandwich setting" where nivolumab is given before and after surgery. Datopotamab deruxtecan, the new kid on the block, takes on the second-line champion docetaxel. Who will win, and will docetaxel finally be dethroned? And potentially the most promising and exciting addition to this lineup is AZD7789, a new bispecific antibody TIM-3 being added to existing immunotherapy to try and resensitise cancer to PD-1 inhibitors!

Studies discussed in today's episode (subscription may be required)

CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639610
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639163
Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638311

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

76. ESMO 2023 - Colorectal Cancer (Part 2)

Wed, 01 Nov 2023 20:00:51 GMT

Metastatic colorectal cancer has an average overall survival of three years. With limited treatment options as standard of care or effective targetable mutations, ESMO23 shined, providing answers to unanswered questions and a potentially brighter future for this cancer. Concerningly, we are seeing higher rates of colorectal cancer in lower and middle-income countries and those under the age of 50. We explore sotorasib in KRASG12C mutated cancers with panitumumab, the use of aspirin to reduce the risk of cancer recurrence and whether triplet therapy is better than double in potentially resectable colorectal cancer.

Studies discussed in today's episode (subscription may be required)

Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638992
First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639062
Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639177

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

75. ESMO 2023 - Colorectal Cancer (Part 1)

Tue, 31 Oct 2023 23:08:22 GMT

Colorectal cancer remains the bread and butter of many an oncologist, but its commonality belies its complexity. In early and advanced disease alike, there remain many permutations, considerations and controversies regarding optimal treatment. What is the best way to treat potentially-resectable colorectal cancer with liver metastases (CRLM)? Is there a way to increase the responsiveness to immunotherapy in patients with proficient mismatch repair (pMMR)? And are we moving to a brighter future where patients with deficient MMR colorectal cancer could avoid surgical management through the miracle of immunotherapy? Ultimately, no one study is going to answer these questions, but with ESMO 2023, we may be starting to peel back the layers of this onion.

Studies discussed in today's episode (subscription may be required)

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638067
Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639575
A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638079

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

74. ESMO 2023 - Upper GI and Hepatobiliary Cancer

Mon, 30 Oct 2023 19:00:41 GMT

Next up on the ESMO 2023 rollercoaster is an episode that is likely to be the shortest in our series: upper gastrointestinal and hepatobiliary oncology. As always, this remains a very challenging subarea of medical oncology, both in the clinical and trial spheres. However, our esteemed colleagues at ESMO remain undaunted by this challenge, and thus several studies of interest bear discussing. Will any of these studies lead to massive upheavals for clinicians and patients alike? For that answer, you'll have to listen on.

Links to studies discussed in this episodes (subscription may be required):

Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638034
GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639003
Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637982

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

73. ESMO 2023 - Genitourinary Cancers - Prostate and Bladder

Mon, 30 Oct 2023 03:57:36 GMT

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make strides in patient care with a phase 1 study that may be lost in no-man land or could harbour a shift in trial design with antibody drug conjugates. Today, we discuss the following trials:

Articles discussed in this episode. Subscription may be required:

Keynote 641 (Pembrolizumab + enzalutamide in the metastatic castrate-resistant prostate cancer sphere)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2819%2930688-6/fulltext
PSMAfore trial (LuPSMA in taxane naive patients)
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639061
MAGNITUDE Study (Niraparib and abiraterone)
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639153
The DAD study (sacituzumab govitecan (SG) plus enfortumab vedotin (EV)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00563-6/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

72. ESMO 2023 - Early Breast Cancer (Part 2)

Fri, 27 Oct 2023 01:02:28 GMT

Welcome back to Oncology for the Inquisitive Mind's ongoing coverage of ESMO 2023. In the spirit of a worldwide oncology conference, here we present results from three very exciting trials in the early breast phase. Will immunotherapy begin to carve out a niche in early, high-risk, ER-positive breast cancer? Can atezolizumab demonstrate a benefit in early TNBC, and expand its own territory? Is abemaciclib pulling away from its rivals in the treatment of high-risk, ER-positive breast cancer? Will managing early breast cancer eventually have a similar success rate to the management of diabetes? And, most importantly, is Michelangelo a better Ninja Turtle than Donatello? The answers to all these questions, and more, lie within.

Studies discussed in this episode (subscription may be required):

Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639087
Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639109
A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639073

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

71. ESMO 2023 - Early Breast Cancer (Part 1)

Wed, 25 Oct 2023 19:00:17 GMT

Every so often, an area of medical oncology has so many interesting presentations at a seminal conference that it becomes impossible to leave them out. At such times, Josh and Michael merely shrug their shoulders and say "why don't we do all of them." ESMO 2023 is one such instance. Despite their best efforts, our intrepid duo were unable to narrow down their presentation of early breast cancer highlights to one episode, so they are going to do two (for the price of one).

Articles discussed in this episode. Subscription may be required

Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637956
Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies
https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637959
Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637966

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

70. ESMO 2023 - Small Cell Lung Cancer

Tue, 24 Oct 2023 19:00:57 GMT

ESMO 2023 showcased several promising trials in the small-cell lung cancer space. A cancer that continues to send shivers down the spine of budding oncologists for decades. Today, we look at several different classes of drugs, the first being a novel immunotherapy agent, the second a well-known antibody-drug conjugate and the third a synthetic alkaloid analogue. Lurbinectedin and pembrolizumab, sacitizumab govitecan or toripalimab, while all difficult to say five times fast, may change the future of small cell lung cancer. Which is your drug of choice? Tune in to find out if you chose correctly!

Studies discussed in this episode. Subscription may be required

EXTENTORCH (Toripalimab) - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639076
LUPER trial (Lurbinectedin + pembrolizumab)- https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638285
Tropics-03 trial (sacituzumab govitecan) - https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638286

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

69. ESMO 2023 - Metastatic Breast Cancer

Tue, 24 Oct 2023 01:19:22 GMT

Michael and Josh continue their examination of the crème-de-la-crème of the European Society of Medical Oncology conference of 2023. Today they focus on metastatic breast cancer, with a particular focus on antibody-drug conjugates (ADCs). T-Dxd, Dato-Dxd and trastuzumab duocarmazine are just three of the many novel agents in this space, and likely represent part of the future (and the present) of medical oncology. How effective are these treatments? Will the final results of the TULIP study blossom like its namesake? Will T-Dxd fulfil its DESTINY and become a treatment option for HER-2 low advanced breast cancer? Will Dato-Dxd assist in making cancer BEGON(IA)? For more excellent puns and the answers to these questions and more, listen on!

Studies discussed in this episode. Subscription may be required

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637914
Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637972
Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637983
First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637984

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

68. ESMO 2023 - Central Nervous System Tumors

Sun, 22 Oct 2023 23:09:44 GMT

Another year, another international oncology conference in a beautiful European locale. In 2023, the world's oncology community has descended on the Spanish capital Madrid to discuss the latest and greatest scientific developments in Medical Oncology. And as always seems to be the case, Michael and Josh remain at home listening to this avalanche of information virtually. Despite a distinct lack of sun and Español, our intrepid duo will continue a grand tradition that dates back to 2022: bringing some of the best highlights from Madrid directly to your ears across a series of episodes to be released this week.

In the first episode of this series, Josh and Michael start in the most difficult of tumour streams: CNS oncology, an area where outcomes continue to be incredibly poor. ESMO 2023 brought some very interesting early-phase trials and no small amount of controversy, but that silver bullet unfortunately continues to elude oncology's brightest minds. Listen on to find out more.

Studies discussed in this episode. Subscription may be required

REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients. https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637999
Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637931
A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637997

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

67. Spotlight: Head and Neck Cancer: Docetaxel as a Radiosensitiser

Sat, 14 Oct 2023 19:00:55 GMT

Cisplatin is the mainstay for concurrent chemoradiotherapy in Locally Advanced Head and Neck Cancers. What happens to that significant group of patients who cannot have cisplatin? Michael and Josh focus on this challenging subgroup of patients. Can docetaxel be used as an alternative? This week, they debut a small but significant segment of our humble podcast called "Spotlight", where we dive deep into a single potentially practice-changing trial. Enjoy!

Links to studies discussed in this episode (subscription may be required):

Docetaxel as a radiosensitiser: https://ascopubs.org/doi/abs/10.1200/jco.22.00980#:~:text=We%20found%20that%20the%20use,of%20life%20of%20the%20patients.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 11: Pulmonary Embolism & Deep Vein Thrombosis in the context of malignancy

Wed, 11 Oct 2023 07:18:22 GMT

Cancer inherently increases the risk of Deep Vein Thrombosis and Pumlmonary Embolism. This is merely a nuisance for some, while others experience significant morbidity, leading to hemodynamic instability and potential death. Historically known as "the great masquerader" with pulmonary embolisms, we explore signs, symptoms, and different approaches to treatment. Warfarin remains the original and is still an option for patients, but have better therapies emerged like direct oral anticoagulants (DOACs)? The short answer is yes, but tune in as we dive again into systematic reviews and give you a summarised version of everything you should know.

Useful Links:

Statpearls DVT: https://www.ncbi.nlm.nih.gov/books/NBK507708/

Anticoagulation for thrombus in malignancy: https://www.uptodate.com/contents/anticoagulation-therapy-for-venous-thromboembolism-lower-extremity-venous-thrombosis-and-pulmonary-embolism-in-adult-patients-with-malignancy?search=cancer%20induced%20DVT&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

66. Gynae-Oncology with Dr Vish Boolell

Sat, 07 Oct 2023 19:00:24 GMT

Gynaecological malignancies are a diverse group of terrible malignancies. From ovarian to endometrial to cervical, these cancers are notorious not just for their mortality burden, but the significant morbidity that they can inflict. To explore how to combat these challenging clinical entities, Michael and Josh interview Dr Vish Boolell, a clinical oncologist who brings his vast practical and trial experience to bear in exploring how to best treat patients and manage the myriad challenges gynaecological cancer can present. Today's episode is a must-listen for anyone who has been confronted by a malignant bowel obstruction, or wondered about the significance of dMMR in endometrial cancer, or who simply want some practical tips about how to best help their gynae onc patients.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

65. Meredith Cummins - CEO of Neuroendocrine Cancer Australia

Sat, 30 Sep 2023 19:00:44 GMT

It is frequently said that it takes a village to treat a patient with cancer. However, beyond the nuts and bolts of medical and allied health treatment, there exists a whole other world of advocacy and education. Charitable and not-for-profit foundations, both nationally and internationally, have done incredible work for many years in raising awareness and funding for cancer treatment and prevention, as well as providing both patient- and doctor-centred education. Oncology for the Inquisitive Mind is incredibly privileged to welcome the CEO of one such organisation, Meredith Cummins of Neuroendocrine Cancer Australia. Meredith brings decades of experience in oncology nursing, governance, fundraising and advocacy, and has done invaluable work in shining a light on the lesser-known challenges facing patients and doctors dealing with neuroendocrine cancers.

Links from this episode:

Neuroendocrine Cancer Australia: https://neuroendocrine.org.au/

PLANET registry: https://neuroendocrine.org.au/planetregistry/

COMPOSE study information: https://trials.cancervic.org.au/details.aspx?ID=feed-cta-trial444

MoST framework: https://www.rarecancers.org.au/page/105/molecular-screening-and-therapeutics-most-#:~:text=MoST%20is%20a%20two%20part,treatments%20and%20new%20drug%20combinations.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

64. Metastatic Neuroendocrine Carcinomas

Sat, 23 Sep 2023 20:00:09 GMT

"I have not failed, I've just found 10,000 ways that won't work!" so said Thomas Edison in describing his journey to the incandescent light bulb. This quote seemed appropraite as Michael and Josh conclude their journey in the neuroendocrine space and discuss neuroendocrine carcinomas (and poorly differentiated metastatic neuroendocrine tumours). Sometimes when you working in the oncological world, we all feel a bit like Thomas Edison, pouring sweat and tears into research that doesn't live up to expectations. But much like Thomas Edison, each step in this journey could revolutionise humanity or oncology, much like the CDK4/6 inhibitors, immunotherapy or tyrosine kinase inhibitors.

But we aren't there yet. This week, Michael discusses the immunotherapy agent (Spartalizumab) while Josh goes old-school and discusses the TOPIC-NEC Japanese trial comparing etoposide and cisplatin (EP) to irinotecan and cisplatin (IP). Michael and Josh smell small cell similarities coming aboard the neuroendocrine express!

Links to studies discussed in this episode (subscription may be required):

TOPIC-NEC: https://jamanetwork.com/journals/jamaoncology/fullarticle/2795418

Immunotherapy (Spartalizumab): https://erc.bioscientifica.com/view/journals/erc/28/3/ERC-20-0382.xml

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

63. Advanced Grade 3 Neuroendocrine Tumours - Chemotherapy options

Sat, 16 Sep 2023 20:00:22 GMT

Neuroendocrine Tumours could be described as an impassable obstacle, more complicated the more you research. That's where Michael and Josh come in, and this week, explore Grade 3 metastatic neuroendocrine tumours. Michael provides a brilliant overview of this well-differentiated cohort and the lack of efficacy platinum chemotherapies have, while Josh discusses CAPTEM (temozolomide and capecitabine) through a systematic review. Interestingly many of the current data is retrospectively collected, highlighting how challenging it is to collect enough patients to pursue meaningful research.

Note- there is a quote from Lance Armstrong, who was stripped of his titles due to illegal doping (which we do not endorse); he did start the Livestrong Foundation to support those affected by cancer.

Links to studies discussed in this episode (subscription may be required):

1. Review - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158108/

2. Cape/tem - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790144/

3. Platinum-based chemo: https://erc.bioscientifica.com/view/journals/erc/20/5/649.xml

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

62. Advanced Neuroendocrine Tumour - Later Lines of Therapy

Sat, 09 Sep 2023 20:00:12 GMT

"We go to the moon and other places not because they are easy, but because they are hard." So spoke US President John F. Kennedy, in a speech that galvanised the American public and fostered widespread support for the space race and the Apollo space program that would culminate in Neil Armstrong and Buzz Aldrin landing on the Moon on July 20, 1969. A similar approach must be taken to the treatment of neuroendocrine tumours, a rare and difficult-to-treat cancer type requiring inventiveness, preparation and lateral thinking (almost) on the level of the Apollo and Soyuz astronauts.

Last week, Michael and Josh discussed the front-line treatment of low-grade, well-differentiated neuroendocrine tumours. However, it always pays to be prepared. To that end, today our intrepid "onconauts" explore the lesser-known frontiers of later options, focussing on the competing everolimus and sunitinib. Will one option triumph over the other and reach the surface of the tumour first? Listen on to find out.

Links to studies discussed in this episode (subscription may be required):

RADIANT: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00817-X/fulltext

Raymond et al (sunitinib): https://www.nejm.org/doi/full/10.1056/nejmoa1003825

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

61. Fireside Chats: What We Call "Cancer"

Tue, 05 Sep 2023 23:13:16 GMT

Between 1933 and 1944, Americans huddled around their radios to listen to the words of Franklin Delano Roosevelt, the 32nd President of the United States. Covering topics ranging from the 1936 recession to World War II, FDR titled these addresses "Fireside Chats", giving very high-concept topics a more personal, intimate feel. Let it never be said that Oncology for the Inquisitive Mind is above shamelessly cribbing ideas from history.

In this series, on the first Wednesday of each month, Josh and Michael will go away from their usual format of data dissection. They will instead turn their attention to a cancer-related article, film or other media and discuss it with the same convivial atmosphere of FDR. In this episode, they discuss a New York Times opinion piece from August 2023 titled "Not Everything We Call Cancer Should Be Called Cancer," trying to strike a balance between personalisation and de-escalation of management of low-risk, pre-cancerous lesions while also viewing such discussions from the perspective of patients.

Article discussed in this episode (subscription may be required):

Not Everything We Call Cancer Should Be Called Cancer, by Dr. Laura Esserman and Dr. Scott Eggener

Available from: https://www.nytimes.com/2023/08/30/opinion/cancer-breast-prostate-treatment.html

Art courtesy of Taryn Silver

Audio courtesy of:

Olexy on pixabay: https://pixabay.com/users/olexy-25300778/
JuliusH on pixabay: https://pixabay.com/users/juliush-3921568/

The opinions discussed in this episode are those of the authors and should not be taken for medical advice. They exist to engender discussion, debate and thought.

Hosted on Acast. See acast.com/privacy for more information.

60. Advanced Neuroendocrine Tumours - Part 1

Sat, 02 Sep 2023 20:00:50 GMT

Neuroendocrine tumours (commonly referred to as NETs) is the topic for this week's episode of Oncology for the Inquisitive Mind. Michael and Josh thought it could be easily covered in a single episode, but they were wrong. This is not dissimilar to the recurrent cancellation of Futurama, a television series with nine lives saved by every network in existence.

Neuroendocrine tumours are a diverse, heterogeneous, rare group of cancers that can occur throughout the body. The most common location is the gastrointestinal tract, lung, and pancreas. Of course, these aren't the only locations with NETs forming in the thymus, prostate, breast and skin. To complicate things further, the classification of NETs has changed multiple times over the past two decades.

This first episode of our four-part "tour de force" will summarise well-differentiated neuroendocrine tumours and the pivotal studies of lanreotide and PRRT (peptide receptor radionucleotide therapy) with lutetium dotatate.

Links to studies discussed in this episode (subscription may be required):

1. Lanreotide - https://www.nejm.org/doi/full/10.1056/nejmoa1316158

2. PRRT - https://www.nejm.org/doi/full/10.1056/nejmoa1607427

3. NCCN guidelines: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

59. Testicular Cancer - Part 2

Sat, 26 Aug 2023 20:00:03 GMT

Previously, on Oncology for the Inquisitive Mind, Josh and Michael discussed the common systemic therapies available for early and advanced testicular cancer: single-dose carboplatin and bleomycin + etoposide + cisplatin (BEP). However, like the beginning of any good story, this is just the beginning. All the knowledge of chemotherapy in the world is nothing without knowing how to apply it. In this episode, our hosts attempt to tackle this very topic, dissecting the when, where and why of the treatment of testicular cancer. Consider this your Hitchikers' Guide to Germ Cell Tumours.

Useful Links from this Episode:

IGCCCG Risk Stratification Guidelines: https://www.urotoday.com/conference-highlights/gsrgt-2020/testicular-cancer/126571-gsrgt-2020-clinical-trials-corner-the-international-germ-cell-cancer-collaborative-group-igcccg-update.html

Review Article - Adjuvant BEP for Stage IB NSGCT: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902120/#B24

eviQ Protocol (TICE): https://www.eviq.org.au/haematology-and-bmt/blood-and-marrow-transplant/autologous/1176-autologous-conditioning-germ-cell-tumour-tice

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 10: Thrombophlebitis and Superficial Venous Thrombosis

Tue, 22 Aug 2023 20:00:43 GMT

On this, the tenth episode of OncoSnacks, Josh and Michael discuss the management of a common but no less important problem: superficial venous thrombosis and thrombophlebitis. While for the majority of cases the treatment is purely symptomatic, in a small minority of cases superficial venous thromboses can be a precursor of more serious thromboembolic events. This broad range of possible outcomes makes the management and risk stratification of apparently minor thromboses all the more important, particularly in the oncology patient population. Listen on as Josh and Michael aim to shed some light in this dark topic.

Useful Links:

BMJ Guidelines on Management of Superficial Thrombophlebitis: ttps://bestpractice.bmj.com/topics/en-us/335

Scott, Mahdi, Alikhan (BMJ Haem): https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13255

Evidence-Based Medicine Guidelines on Management of Superficial Thrombophlebitis: https://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00920#:~:text=The%20recommended%20treatment%20

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

58. Testicular Cancer - Part 1

Sat, 19 Aug 2023 20:00:27 GMT

Edward Gibbon, an English historian and politician, once quipped, "History is indeed little more than the register of the crimes, follies, and misfortunes of mankind." This episode, which lacks historians and politicians, covers testicular cancer, a topic humankind has had a love-hate relationship with for millennia. As a historical concept in the middle ages, men who wanted to have a male as an offspring would sometimes remove their left testicles as the belief was that "boy" sperm was made in the right testicle and "girl" sperm in the left.

We don't entertain such nonsense here on Oncology for the Inquisitive Mind. Instead, we discuss testicular cancer, an uplifting episode with high cure rates and a debate regarding observation versus treatment. Will there be a future when one can perform surgery alone? Does radiotherapy have a role, and do the pros outweigh the cons of chemotherapy?

Links to studies discussed in this episode (subscription may be required):

EORTC 30982 study: https://pubmed.ncbi.nlm.nih.gov/21282539/

Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial: https://academic.oup.com/jnci/article/102/16/1253/2568956

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

57. ROS1 and KRAS Mutated Lung Cancer

Sat, 12 Aug 2023 20:01:40 GMT

In this episode, the Nautilus reaches its final destination, where Michael and Josh pursue a deeper understanding of ROS1, and KRAS mutated lung cancer. ROS1 reflected less than 3% of non-small cell lung cancer, while KRAS is abundant and can reflect up to 25% of lung cancer patients. The challenge lies in the targets, with the only approved KRAS treatment sotorasib targeting a single KRASG12C mutation. Many, many more KRAS mutations exist in the wild. Michael uses his oxygen tank to discuss an integrated efficacy and safety analysis of entrectinib, and Josh breaks free of a shark and highlights the CodeBreaK 200 study.

Links to studies discussed in this episode (subscription may be required):

CodeBreaK 200: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00221-0/fulltext

Integrative Analysis: https://pubmed.ncbi.nlm.nih.gov/31838007/

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

56. ALK-mutant Metastatic Lung Cancer

Sat, 05 Aug 2023 20:00:21 GMT

In this episode, Michael and Josh step onto the oncological Nautilus, to begin their journey 20,000 Leagues Under Lung Cancer, to examine non-small cell lung cancer with mutations other than EGFR. The first step on their journey is discussing the anaplastic lymphoma kinase, a tyrosine kinase inhibitor associated with the development of non-small cell lung cancer in younger patients who have never smoked. Thankfully, unlike their previous episode, there are treatment options galore for patients with ALKmut NSCLC. Two of the contenders for the title of "The King of the ALK" are alectinib and lorlatinib. Alectinib has more robust overall survival data, but lorlatinib has hazard ratios so ridiculously good that they would almost meet statistical significance as p values! So which is better? Listen on to find out.

Links to studies discussed in this episode (subscription may be required):

ALEX: https://www.nejm.org/doi/full/10.1056/nejmoa1704795

CROWN: https://www.nejm.org/doi/full/10.1056/NEJMoa2027187

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

55. Extensive-Stage Small Cell Lung Cancer

Sat, 29 Jul 2023 20:00:55 GMT

There are cancers that grow slowly. There are cancers that do not grow at all. And then there are cancer's like today's subject, that are notorious not just for their ability to completely overcome a patient in a very small amount of time. Extensive-stage small cell lung cancer remains a very difficult condition to treat, highly prone to relapse and with few effective options beyond - or perhaps even including - the first line setting. While the medical and scientific community remain stalwart in their quest for therapeutic options, success stories have been few and far between. In this episode, Josh and Michael look at one success story, and one study dredged up from the pre-Internet era, to illustrate the dichotomy and discuss the challenge of treating this, the most aggressive of solid tumours.

Links to studies discussed in this episode (subscription may be required):

IMpower133: https://www.nejm.org/doi/full/10.1056/nejmoa1809064

von Pawel et al.: https://ascopubs.org/doi/10.1200/JCO.1999.17.2.658?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 9: Chemotherapy Extravasation

Tue, 25 Jul 2023 20:00:46 GMT

Chemotherapy extravasation can occur day or night, and one must always be vigilant. While many agents are irritants and may not pose significant risks, vesicants pose a different story. A tale of danger and intrigue, this situation can lead to the involvement of a friendly neighbourhood surgeon or Spiderman. In worst-case scenarios, significant tissue damage, treatment delay, and a sizeable psychological burden on the patient can occur. In this OncoSnacks episode, Michael and Josh explore this world, highlighting potential agents and how to prevent, diagnose and manage them.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

54. Cancer Survivorship with Dr Ash Malalasekera

Sat, 22 Jul 2023 20:00:53 GMT

Cancer is thought of as a great killer, an indefatigable bogeyman that claims the lives of everyone it afflicts. However, advances in medicine mean that for more people than ever before, cancer is something that people can survive or at least live with for longer. While an incredible achievement, this does raise many new challenges for patients and physicians alike. And thus, the concept of Cancer Survivorship was born, a service that aims to fill the gap in service for patients who have survived, or are surviving with cancer but may feel somewhat adrift in stormy seas.

In this episode of Oncology for the Inquisitive Mind, Josh and Michael interview Dr Ash Malalasekera, an oncologist working in the South Western Sydney Local Health District, Chris O'Brien Lifehouse and Concord Repatriation Hospital, who has incredible insight into this emerging and truly holistic approach to the care of patients with cancer. We ask about her experiences, the challenges of this model of care and how it can improve or, in some cases, transform how patients can embrace life with or after cancer.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

53. Ductal carcinoma in situ (DCIS) and Lobular carcinoma in situ (LCIS)

Sat, 15 Jul 2023 20:00:52 GMT

DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in situ) are challenging areas of breast cancer oncology. Michael and Josh return from their short hiatus to find their podcast has been ranked one of the top oncology podcasts by feedspot. Do not fear; they won't rest on their laurels and are ready to roll and bring another exciting episode of management, intrigue, and choose your adventure. Neither DCIS nor LCIS are technically cancer, but they both have the propensity to develop into a malignancy. The benefit versus toxicity question becomes paramount in the episode when talking to patients about cancer risk and treatment options. What on earth does a precancerous lesion actually mean?

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

If you are interested in other Oncology Podcasts, head to feedspot to find out more: https://blog.feedspot.com/oncology_podcasts/#rightModal

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

52. ASCO 2023 - Plenary Session

Tue, 13 Jun 2023 20:00:02 GMT

Theodore Roosevelt is famously quoted saying: "It is hard to fail, but it is worse never to have tried to succeed." This is what ASCO, oncologists and cancer researchers are faced with daily. As our tour de force of ASCO 2023 ends, and we foresee a future where daily episodes don't arrive, we present our final episode. Michael and Josh have kept three of the most exciting trials until the end.

Today, three plenary sessions are reviewed. The first is in gliomas, the second in adjuvant lung cancer treatment, and finally, Michael and Josh tackle Mount Everest and the confusing world of rectal cancer with PROSPECT, a trial looking at non-inferiority and toxicity.

Studies

INDIGO: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA1

ADAURA: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA3?af=R

PROSPECT: https://meetings.asco.org/abstracts-presentations/219804

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

51. ASCO 2023 - Melanoma & Head and Neck

Mon, 12 Jun 2023 20:00:45 GMT

The epic journey of Josh and Michael across tumour streams at ASCO 2023 is approaching its end. It has been a whirlwind tour through groundbreaking science, hazard ratios and exciting glimpses into a brighter future for cancer patients. However, our intrepid duo's work is not yet done, merely reached its penultimate stage. In today's episode, Josh and Michael examine four notable studies in the spheres of melanoma and head and neck cancer. Spoiler alert: in this part of the map, here there be groundbreaking studies!

Studies

Fianlimab + cemiplimab: https://meetings.asco.org/abstracts-presentations/218502

KEYNOTE-942: https://meetings.asco.org/abstracts-presentations/218505

CONTINUUM: https://meetings.asco.org/abstracts-presentations/218513

DEPEND: https://meetings.asco.org/abstracts-presentations/218516

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

50. ASCO 2023 - Metastatic NSCLC

Sun, 11 Jun 2023 20:00:33 GMT

Every epic journey has that moment when the end is in sight. The start of the last lap of the race, the final dramatic encounter with the main villain. On this episode of Oncology for the Inquisitive Mind, that villain is metastatic lung cancer, with a particular focus on EGFR mutant disease. There have been a lot of questions raised about the best next step after the failure of the star of ASCO 2023: osimertinib. Here, Josh and Michael examine three breaking studies that seek to shed some light on the slowly-unravelling mystery of how to best sequence and treat EGFR mutant advanced non-small cell lung cancer.

Finally, as we surpass fifty episodes, we wanted to say a huge thank you to everyone who has joined us on Oncology for the Inquisitive Mind so far. We have gone from two guys completely ignorant to the ways of podcasting to two guys almost completely ignorant to the ways of podcasting with a burgeoning, supportive and engaging community. For that, we cannot thank you enough. We love bringing this content to you, and we cannot wait for the next fifty episodes. We have a lot of exciting stuff yet to come!

Studies

KEYNOTE-789: https://meetings.asco.org/abstracts-presentations/218083

EVEREST: https://meetings.asco.org/abstracts-presentations/218106

WU-KONG6: https://meetings.asco.org/abstracts-presentations/218846

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

49. ASCO 2023 - Metastatic Breast Cancer

Sat, 10 Jun 2023 20:00:04 GMT

Cancer is facing a seismic shift as precision oncology is becoming a reality, and adoption is skyrocketing as new anti-cancer agents are released. It appears that the days of blunt-force chemotherapy could be limited. Paul Ehrlich, the German Chemist, is credited with the term "chemotherapy", but more importantly, the concept of the magic bullet, "zauberkugel", which would allow selective targeting of pathogenic microbes without affecting other parts of the body. Leading the field of targeting cancer is metastatic breast cancer, as demonstrated by ASCO23. Oncology for the inquisitive Mind explores CDK4/6 sequencing, antibody-drug conjugates, and HER3 targeted therapy. Michael and Josh dissect the SONIA trial, sacituzumab govitecan use in the hormone receptor-positive space and partritumab deruxtecan, which could have pan-breast cancer utility.

Studies

SONIA: https://meetings.asco.org/abstracts-presentations/219701

TROPICS-02: https://meetings.asco.org/abstracts-presentations/219698

PARTRITUMAB DERUXTECAN: https://meetings.asco.org/abstracts-presentations/219699

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

48. ASCO 2023 - Prostate, Bladder and Renal Cancer

Fri, 09 Jun 2023 20:01:26 GMT

ASCO 23 explored novel anti-cancer agents in the genitourinary space. The future of oncology is etching closer daily. In this episode, Michael and Josh dissect ertafitinib, an FGFR inhibitor used in bladder cancer, talazoparib in prostate cancer and immunotherapy and TKI combinations in renal cell cancer. All these studies reflect the desire to target cancers further with some astonishing results.

Studies

THOR: https://meetings.asco.org/abstracts-presentations/217894

PEACE-1: https://meetings.asco.org/abstracts-presentations/218388

TALAPRO-2: https://meetings.asco.org/abstracts-presentations/222733

RENAL CELL CARCINOMA: https://meetings.asco.org/2023-asco-annual-meeting/15007?presentation=219853#219853

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

47. ASCO 2023 - Colorectal Cancer

Thu, 08 Jun 2023 20:00:13 GMT

ASCO 2023 has been an incredible journey, and the latest instalment of Michael and Josh's search for the latest and greatest oncological news is no exception. On this episode, our intrepid duo examine three studies with potentially practice-changing consequences, like Burton and Speke quest for the source of the River Nile. Which, in this ASCO series is literally just another day at the office. But will the presented evidence live up to the promise provided by its premise? You'll have to listen on to find out!

Studies

Destiny-CRC02: https://meetings.asco.org/abstracts-presentations/218394

NeoCol: https://meetings.asco.org/abstracts-presentations/219419

PRODIGE-23 Update: https://meetings.asco.org/abstracts-presentations/219425

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

46. ASCO 2023 - Early Lung Cancer

Wed, 07 Jun 2023 20:00:05 GMT

In this episode, Michael and Josh investigate Lung Oncology research presented at ASCO 23, specifically early lung cancer treatment. They discuss Perioperative Toripalimab, LAG3 inhibitor Relatlimab and the new novel agent BI 764532, a novel DLL3-targeting T cell engaged.

Studies:

NEOTORCH: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.36_suppl.425126

NEOPREDICT: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8500

DLL3-positive SCLC: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8502

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

45. ASCO 2023 - Gynaecologic Cancers

Tue, 06 Jun 2023 20:00:57 GMT

Ovarian, cervical and endometrial cancer need more treatment options. Platinum-based chemotherapy only works for so long. ASCO 23 delivers with the practice-changing MIRASOL study introducing Mirvetuximab Soravtansine, a novel ADC with efficacy in ovarian cancer. Michael and Josh also discuss the Oval Study (ofranergene obadenovec) and immunotherapy in the DUO-O trial and Keynote 826. Not all trials are equal, and this OftIM ASCO special explores endpoints, hazard ratios and comparisons.

Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.

Studies:

MIRASOL: https://meetings.asco.org/abstracts-presentations/226803

OVAL: https://meetings.asco.org/abstracts-presentations/218323

DUO-O: https://meetings.asco.org/abstracts-presentations/220048

Keynote-826: https://meetings.asco.org/abstracts-presentations/220048

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

44. ASCO 2023 - Central Nervous System

Mon, 05 Jun 2023 20:00:31 GMT

Captain's Log: ASCO Day 3.

Today's episode brought myriad developments in treating CNS cancers and brain metastases from other distant lands. Some studies offered new and exciting targets for potential treatments. Others purported to provide benefits in new and exciting ways, eschewing infusions and tablets with vaccinations. Still, others repurposed old technology in new ways, investigating uses for things we already had.

Unfortunately, many of the solutions were premature and primitive in their exploration. Much further study is required. We will continue to observe these trials for outcomes, but we hope they will yield answers in our quest to fight the disease plaguing our crew.

Studies discussed:

Anti-PD-1 + GITR + RTx: https://meetings.asco.org/abstracts-presentations/218240

UCPVax: https://meetings.asco.org/abstracts-presentations/219832

Pembrolizumab in CNS metastases: https://meetings.asco.org/abstracts-presentations/218261

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

43. ASCO 2023 - Early Hormone Receptor Positive Breast Cancer

Sun, 04 Jun 2023 20:00:20 GMT

Hormone receptor-positive breast cancer again takes centre stage at the ASCO 23 (American Society of Clinical Oncology) Annual Meeting and has reinvented itself over the last two decades. Improvements are occurring in the adjuvant and neoadjuvant setting for both estrogen (ER) and progesterone (PR) positive and the human epidermal growth factor receptor space (HER2). In this episode, Michael and Josh take a closer look at MonarchE (Abemaciclib), NATALEE (Ribociclib), PHERgain (dose de-escalation) and Penelope-B (ctDNA).

As the arsenal for treating breast cancer grows, a crowded space means ongoing challenges with sequencing and choice of therapy.

Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.

Studies:

MonarchE: https://meetings.asco.org/abstracts-presentations/218406

NATALEE: https://meetings.asco.org/abstracts-presentations/218407

PHERgain: https://meetings.asco.org/abstracts-presentations/219848

Penelope-B: https://meetings.asco.org/abstracts-presentations/220878

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

42. ASCO 2023 - Gastroesophageal, Pancreatic and Hepatobiliary update

Sun, 04 Jun 2023 05:59:23 GMT

ASCO 23 (American Society of Clinical Oncology) Annual Meeting in Chicago showcased a plethora of cutting-edge trials and research. Upper gastrointestinal cancers such as gastric, pancreatic and hepatobiliary are usually relegated to the backstage, but this year, several exciting and potentially practice-changing studies (not without their limitations).

We explore a new PD-1Toripalimab in gastric and gastroesophageal cancer, liposomal irinotecan in NALIRIFOX versus gemcitabine/abraxane in metastatic pancreatic cancer, neoadjuvant FOLFIRINOX in pancreatic cancer and the new HER2 kid on the block zanidatamab, a bispecific monoclonal antibody.

Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.

Studies:

Toripalimab + SOX study: https://meetings.asco.org/abstracts-presentations/219777

NAPOLI-3 study: https://meetings.asco.org/abstracts-presentations/222090

NORPACT-1 study: https://meetings.asco.org/abstracts-presentations/219426

HORIZON-BTC-01 study: https://meetings.asco.org/abstracts-presentations/219904

Special Mention (not included in the episode)

DIPLOMA Study: https://meetings.asco.org/abstracts-presentations/218312

Lauren Classification: https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodes

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

41. Pre-ASCO Appetizer

Fri, 02 Jun 2023 11:00:59 GMT

*SPECIAL EPISODE ALERT*

Every year, Josh and Mike cross their fingers and pray to Father Conference-Leave that they can make the pilgrimage to one of the two central sites of Oncology: Madrid for ESMO or Chicago for ASCO. Unfortunately, to this point, Father Conference-Leave has not delivered, and 2023 is no different. However, the cold and wind will not stop our intrepid hosts from parsing the avalanche of potentially practice-changing studies, agents and professional development about to descend on the Windy City

So, consider today's episode what our American listeners would call an "appetizer," a taste of what may be coming from the American Society of Clinical Oncology Annual Meeting for 2023. This will be followed by a string of episodes breaking the aforementioned avalanche down and examining it with a fine tooth comb, with one episode dedicated to each tumour stream. So, do not adjust your set, as there will be a huge amount of Oncology content coming your way. As well as some helpful hints about North American geography.

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023, but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 8: Chemotherapy-induced Peripheral Neuropathy

Tue, 30 May 2023 20:02:23 GMT

Peripheral neuropathy is a common toxicity of multiple anticancer agents used to treat and cure cancer, including platinum, taxanes and vinca alkaloids chemotherapy. These chemotherapy classes are as ubiquitous for cancer treatment as the sun is to plant photosynthesis. This week on OncoSnacks, Michael and Josh investigate what to do when a patient has peripheral neuropathy and examine existing evidence for prevention, treatment and duration of this sequelae.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

40. Advanced Endometrial Cancer

Sat, 27 May 2023 20:00:57 GMT

It is always nice to be able to say the phrase: "This cancer has an excellent prognosis." That is the case with endometrial cancer, which for the majority of sufferers, can be cured and carries an excellent survival. However, there are cases that unfortunately present late, and for these patients, the outlook is significantly more grim.

Some oncologists have little experience treating advanced endometrial cancer; for those listeners, this episode is specifically for you! In our 40th episode, Josh will discuss the foundations of endometrial cancer treatment, a topic that is vital but very boring, much like Josh himself. Michael will discuss the new frontier of immunotherapy in dMMR endometrial cancer, something that is transformative and very exciting but also unfortunately irrelevant to the majority of patients, much like Michael.

Links to studies discussed in this episode (subscription may be required):

GOG0209: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676887/

RUBY: https://www.nejm.org/doi/full/10.1056/NEJMoa2216334

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

39. Leadership, Policy and Teletrials with Prof Sabe Sabesan

Sat, 20 May 2023 20:05:31 GMT

COSA President-elect (Clinical Oncology Society Australia), Professor Sabe Sabesan, is the oncologist and doctor we all dreamed of being when starting our medical training. This is a story of adversity, compassion and drive without compromise. Sabe's global journey has taken him to some of the remotest places on earth, with each inflection point creating new challenges and opportunities. We discuss advocacy, the rollout of teletrials to improve equitable access, redefining system issues with the lasagna model and looking after the little guy. Michael and Josh are the OFTIM team and are humbled to share Sabe's story, a tale many of us can only aspire to achieve.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 7: Cardiotoxicity with Dr Mark Nolan

Tue, 16 May 2023 20:00:24 GMT

On Oncology for the Inquisitive Mind, we like to focus on cancer and available treatment options. However, every oncologist is at his or her best when working hand-in-hand with other specialities. In this, our seventh episode of OncoSnacks, Michael and Josh interview Dr Mark Nolan, a non-invasive cardiologist with a special interest in anti-cancer treatment-induced cardiotoxicity. Mark provides an engaging, comprehensive overview of the diagnosis and management of cardiotoxicity, with a particular focus on the two usual culprits: anthracyclines and anti-HER2 agents. A must listen for anyone who has been confronted with a left ventricular ejection fraction (LVEF) of 40%...I mean 30%... oh, now it's 20%...

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

38. Adenoid Cystic Carcinoma - Rare Cancer Snapshot

Sat, 13 May 2023 20:05:29 GMT

Adenoid Cystic Carcinoma (ACC) is a rare cancer commonly found in the head and neck region, arising from glandular salivary tissue. Like many orphan cancers, effective treatments in the metastatic setting are needed desperately. The 5-year survival rate is 80% and declines over time. In this special subseries: Rare Cancer Snapshots, Michael and Josh pour over the evidence for ACC, pathophysiology and the treatment paradigm to date.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

37. Metastatic Castrate Resistant Prostate Cancer- Theranostics and Chemotherapy

Sat, 06 May 2023 20:05:52 GMT

Lutetium PSMA (Lutetium-177), theranostic medicine and future advances in prostate cancer are coming to an oncology centre near you faster than you can say "novel drug development" and "progression-free survival". This week Michael and Josh conclude their epic prostate cancer trilogy by exploring theranostic medicine and radioactive drug development while looking at the past of the cytotoxic world and the role of cabazitaxel. To ensure we keep your attention, six trials are discussed today, and a shout out to TheraP, the Australian phase 2 trial from the land down under.

Links to studies discussed in this episode (subscription may be required):

Tropic trial: https://www.thelancet.com/article/S0140-6736(10)61389-X/fulltext

CARD trial: https://www.nejm.org/doi/full/10.1056/nejmoa1911206

Corn et al: https://pubmed.ncbi.nlm.nih.gov/31515154/

TheraP: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltext

Vision: https://www.nejm.org/doi/full/10.1056/nejmoa2107322

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

36. Early Drug Development and Mentorship with Dr Jenny Liu

Sat, 29 Apr 2023 20:00:03 GMT

Every feast needs a palate cleanser. Every great work of theatre needs an intermission. Every sports event needs a half-time show. In this way, Oncology for the Inquisitive Mind is no different to Hamilton or the Super Bowl. Here, we provide a little deviation from our ongoing Prostate Cancer Saga to interview Dr Jenny Liu, Oncologist and early drug development (EDD) researcher extraordinaire. Our discussions range from her slightly unusual path to oncology, her previous research and how it is still making waves in the oncological community, and her other great passion: mentorship. Suppose you are interested in Phase One trials, mentorship opportunities (especially in Australia), or simply enjoy Josh dredging up dirt on highly accomplished clinicians. In that case, this is the episode for you!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

35. Castration-Resistant Prostate Cancer

Sat, 22 Apr 2023 20:00:49 GMT

In the second episode of our prostate-cancer series, we investigate the inevitability of castration resistance: the biochemical, radiological and clinical progression of prostate cancer despite the best efforts of the heroic MDT. While this space will likely change in the coming years, with many novel anti-androgen agents displaying efficacy in the HSPC space, the current standards of care for patients include docetaxel and the dynamic duo of abiraterone + prednisolone and enzalutamide. These latter two agents are frequently used in the first line when a patient cannot or is unlikely to tolerate docetaxel chemotherapy.

However, there can only be one Lord of the Anti-Androgens, and today Josh and Michael will reveal their preferred agent. Listen on to find out which, and please, contain your excitement.

Links to studies discussed in this episode (subscription may be required):

PREVAIL: https://www.nejm.org/doi/full/10.1056/nejmoa1405095
COU-AA-302: https://www.nejm.org/doi/full/10.1056/nejmoa1209096
TAX-327 (cameo only): https://www.nejm.org/doi/full/10.1056/nejmoa040720

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 6: Immunotherapy-related Thyroid Disorders with Endocrinologist Dr Dahlia Davidoff

Tue, 18 Apr 2023 20:05:08 GMT

Endocrinopathies in immunotherapy-related cancer treatment are common! Most of us will experience patients with hyperthyroidism and hypothyroidism regularly and recurrently in everyday practice. The incidence is variable, with some sources stating as high as 40% and others as low as 10%; either way, oncologists and trainees are likely to be close allies with their friendly neighbourhood endocrinologist. This week on Oncosnacks, Michael and Josh are interviewing Dr Dahlia Davidoff, an endocrinologist at North Shore Private Hospital in Sydney. Dahlia completed her specialist training through the prestigious Alfred Health and is currently a PhD student researching endocrine cancers at the Kolling Institute of the University of Sydney.

They focus predominantly on thyroid disorders and how to diagnose and optimise these conditions with patients receiving immunotherapy

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Dahlia Davidoff details:

https://www.davidoffendocrinology.com/

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

34. Hormone-Sensitive Prostate Cancer (2)

Sat, 15 Apr 2023 20:00:11 GMT

J.R.R. Tolkien. George Lucas. Steven Spielberg. With such seminal trilogies as Star Wars, the Lord of the Rings and Indiana Jones achieving a permanent place in the psyche of everyday life, who would have thought there would be room for more? But fear not, because Michael and Josh are here with their take on the age-old formula, with the first in a trilogy of episodes on prostate cancer. Just as Luke Skywalker discovered his heritage and embarked on an epic quest against the Empire, so too do our heroes take their first steps in a fight of their own, examining two studies that pave the way for the future in hormone-sensitive prostate cancer (HSPC) treatment. Gone are the days of ADT-alone, fading to give way to a newer, brighter future, like the end of Tolkien's Third Age. In summary, one may say of the old vogue of HSPC treatments: "It belongs in a museum!"

Have we mentioned that we are MASSIVE nerds recently?

Links to studies discussed in this episode (subscription may be required):

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

33. Ageism and Geriatric Oncology with Dr Michael Krasovitsky

Sat, 08 Apr 2023 20:05:01 GMT

Ageism is an inherent bias seen throughout medicine, with cancer adding complexity to an already difficult set of circumstances. Despite our best efforts, we all must face growing older, with time itself being that unstoppable force. Over 50% of all new cancer diagnoses are in the over-65 age bracket, which will climb as ageing populations become a reality across the globe.

This week, Michael and Josh interview the charismatically delightful Dr Michael Krasovitksy, a staunch supporter and advocate of self-empowerment, geriatric oncology and self-determination in the oncological world. Multiple thought-provoking topics are covered, including ageism, toxicity, symptom management, geriatric oncology, holistic medicine and how to combat the creeping presence of frailty. We also debate the age-old question: When do we not treat, and how does one have this conversation with the outcome being a guaranteed ticket to "shuffle off this mortal coil"?

This is one episode where Michael and Josh might find themselves with more questions than answers.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Hosted on Acast. See acast.com/privacy for more information.

Oncosnacks 5: Anti-Cancer Treatment-Induced Alopecia

Tue, 04 Apr 2023 20:05:57 GMT

This episode of OncoSnacks pays homage to the lack of eyebrows, eyelashes and hair many patients face when undergoing cancer treatment and the resultant alopecia. While chemotherapy is the most wanted agent, it alone is not to blame. Michael and Josh explore the hairy situation of hair loss that faces many of our patients as they navigate a new world of outpatient clinic appointments, infusion centres and a new reality in how they live and look.

No eyebrows were injured during the making of this episode.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

32. Oligometastatic Colorectal Cancer - Is it curable?

Sat, 01 Apr 2023 20:00:41 GMT

Today, our intrepid trio once more plunge down 20,000 leagues, exploring the confusing depths, hoping to answer one question: is there any evidence to support using systemic therapy in patients with potentially resectable oligometastatic colorectal cancer? The answer will take them to many dark, barely-explored corners of their profession and will raise more questions than answers. Following in the forebears of many explorers, it may drive them completely mad, or at least madder than they already are. But, to paraphrase Captain Nemo of the Nautilus: "the Earth does not want new continents, but new evidence for patients with resectable metastatic colorectal cancer."

Links to studies discussed in this episode (subscription may be required):

OLIVIA: https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035

Falcone et al.: https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

TRIBE: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20Italian

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

31. Metastatic Head and Neck Cancer

Sat, 25 Mar 2023 19:00:53 GMT

Michael and Josh welcome back Dr Andrew Jensen to help explore part two of OftiM's Head and Neck Cancer exploration party. With localised treatments done and dusted, the metastatic space is a daunting heterogeneous disease group. Twenty years ago, head and neck treatment relied on tried and true chemotherapy, but the last fifteen years have shown great strides regarding treatment options and outcomes. The first leap forward was cetuximab added to a chemotherapy backbone, making it the weapon of choice for oncologists worldwide. But like all great civilisations, pembrolizumab now dominates, showing how it can be effective when combined with existing treatment options.

A star-studded episode and one not to be missed!

Links to studies discussed in this episode (subscription may be required):

NCT00122460- https://www.nejm.org/doi/full/10.1056/nejmoa0802656
Keynote 048- https://www.thelancet.com/article/S0140-6736(19)32591-7/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Hosted on Acast. See acast.com/privacy for more information.

30. Early Head and Neck Cancer

Sat, 18 Mar 2023 19:00:27 GMT

30 episodes ago, two young doctors took their first steps into the podcasting sphere, stumbling like two newborn foals birthed into a paddock full of fully functioning stallions, presenting a niche. Since then, they have blossomed before your ears into two vaguely competent podcasters, still finding their feet but growing in confidence, if not skill. Our continued existence, we owe entirely to you, our wonderful audience. You are the reason we continue to front up to our microphones every week, often wearing our pyjamas but that's beside the point. What we're trying to say is thank you, from the bottom of our hearts.

To express our gratitude, we have prepared a niche episode for our niche podcast, examining the treatment of early head and neck cancer. This topic can befuddle even the most experienced oncologists with its confusing, contradictory cornucopia of confirmatory cancer clues. So listen on, as Michael and Josh try to clear a path through the dense jungle, like Doctor Livingstone BEFORE he went missing. Have I met my metaphor quota yet?

Links to studies discussed in this episode (subscription may be required):

JCOG1008: https://ascopubs.org/doi/full/10.1200/JCO.21.01293

Induction chemotherapy for NPC (Zhang et al.): https://www.nejm.org/doi/10.1056/NEJMoa1905287?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 4: Immune-Mediated Pneumonitis

Tue, 14 Mar 2023 19:00:49 GMT

This episode of OncoSnacks kicks off Michael and Josh's sojourn into the wide world of immune-mediated adverse effects. Inevitably, as most blowhards do, they begin with the lungs. Immune-mediated pneumonitis is not as common as endocrine-axis abnormalities, dermatitis or colitis, but it can be insidious and devastating in equal measure. Such is the potential impact that must be considered in any patient who has received immunotherapy and presents with dyspnoea or a dry cough. Listen to learn more, and you will also know what irAEs and Senator Joseph McCarthy have in common.

Guidelines for the management of Immune-Mediated Pneumonitis are available at:

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

29. Metastatic Hormone Receptor (HR) Positive Breast Cancer

Sat, 11 Mar 2023 19:29:52 GMT

Five hundred years ago, Christopher Columbus set forth to explore unknown lands. You might be asking, what do Chris and metastatic hormone receptor-positive breast cancer have in common? The answer lies in his diaries, a tale of two men, with one aptly providing anatomical details of our subject today. While we spend little time exploring Christopher, Michael and Josh meet and greet three famed Cyclin Dependant Kinase Inhibitors (CDK4/6) commonly known as Ribociclib, Abemaciclib and Palbociclib. While not all equal in stature, they have revolutionised metastatic breast cancer and now stand as first-line therapy and the gold standard of treatment. Tune in to find out why!

Visit us at your new website, www.inquisitiveonc.com, for our latest episodes, links to resources and musings!

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver. Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice, and for health, practitioners ensure you refer to your local institution's guidelines for treatment recommendations.

Hosted on Acast. See acast.com/privacy for more information.

28. ASCO GU 2023 Spectacular

Sat, 04 Mar 2023 19:00:42 GMT

For the second time in 2023, Josh and Michael discuss some of the hardest-hitting highlights from a conference; in this case, they dive into five studies that caught their eye at the recent ASCO GU Conference in, in Michael's words, "sunny California." We think he is simply jealous of the fact that Melbourne barely has sunshine for most of the year. Never fear: the amount of grousing about the weather pales in comparison to the clinical pearls, future projections and terrible puns.

Studies Discussed: ARASENS, CaboPoint, TALAPRO, HCRN GU14-188, PROpel, TROPHY-U-01, CAPTURE

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 3: Chemotherapy-Induced Nausea and Vomiting

Tue, 28 Feb 2023 19:00:36 GMT

In this episode of OncoSnacks, Josh and Michael address the classic chemotherapy side effect: nausea. From Terms of Endearment (1983) to ER (2002), from Breaking Bad (2008) to Archer (2011), nausea and vomiting are the most frequently imagined side effects when it comes to chemotherapy. However, we are much better at managing chemotherapy-induced nausea and vomiting (CINV) than we once were; a combination of better antiemetics and move away from highly emetic therapies means patients are usually much better off perspective. Nevertheless, in the words of great ancient oncologist Sun Tzu: "if one knows oneself, and knows the neuronal pathways associated with chemotherapy-induced nausea and vomiting, one need not fear the result of a thousand infusions." Listen on to find out how!

Guidelines for management of CINV available at:

- https://www.sciencedirect.com/science/article/pii/S2468294220301131

- https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/7-prevention-of-anti-cancer-therapy-induced-nausea

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

27. High Grade Gliomas and Glioblastoma Multiforme (GBM)

Sat, 25 Feb 2023 19:00:41 GMT

Concluding their Journey to the Centre of the Brain, Michael and Josh tackle one of the most challenging and difficult cancers in modern oncology: high-grade gliomas. All of the usual suspects are here: irrevocable, progressive disease, limited treatment options and a gulf in evidence so large it makes the Grand Canyon look like a muddy footprint. All in all, not the most optimistic of OftiM episodes, but Josh and Michael will tackle it anyway so you don't have to. And remember: always refer your fit GBM patients to a friendly neighbourhood trials unit near you!

Links to studies discussed in this episode (subscription may be required):

EORTC 26981-22981 NCIC CE3 (aka the “Stupp study"): https://www.nejm.org/doi/full/10.1056/nejmoa043330

RTOG 0825: https://www.nejm.org/doi/full/10.1056/nejmoa1308573

Brada et al: https://ascopubs.org/doi/full/10.1200/JCO.2009.27.1932?role=tab

Taal et al: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70314-6/fulltext

Wick et al: https://www.nejm.org/doi/full/10.1056/nejmoa1707358

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Visit us at your new website www.inquisitiveonc.com for our latest episodes, links to resources and musings!

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

26. Neuro-Oncology

Sat, 18 Feb 2023 21:20:42 GMT

Oncology for the Inquisitive Mind finally embarks on the treacherous journey of neuro-oncology. While researching for this episode, Michael and Josh realised that effective treatments are limited but do not reduce neuro-oncology's complexity. This is a hefty episode covering low-grade gliomas, oligodendroglioma, astrocytomas and the important molecular markers and how these influence survival and prognosis for our patients. It also talks about the new WHO classification of primary brain tumours and how it has affected the interpretation of prior research.

Tune in for part one of this special mini-series covering neuro-oncology

Link: https://www.atlasantibodies.com/blog/glioma-classification-and-key-molecular-pathology/

External site, no subscription is required

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 2: Chemotherapy-induced Diarrhea

Tue, 14 Feb 2023 19:05:00 GMT

In our second bite-sized episode, Michael and Josh explore the challenge of chemotherapy-induced diarrhoea, a common problem for patients leading to morbidity, hospital admissions, and potentially stopping curative treatments early. While immunotherapy and targeted therapy are not innocent bystanders regarding colitis and bowel problems, chemotherapy has long been the most prominent protagonist of this story. It is essential to identify warning signs, investigate adequately and see the treatment options available to you, the saviour and potential part-time plumber. Tune in and find out more!

eviQ reference guide on diarrhea: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/779-treatment-induced-diarrhoea#:~:text=Chemotherapy%2Dinduced%20diarrhoea%20usually%20occurs,cause%20diarrhoea%20at%20other%20times.

BC Cancer reference guide on diarrhea:

http://www.bccancer.bc.ca/nursing-site/Documents/4.%20Diarrhea.pdf

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

25. ASCO GI 2023 Extravaganza

Sat, 11 Feb 2023 19:00:24 GMT

In the grand, six-month-long tradition of Oncology for the Inquisitive Mind, Josh and Michael provide an update from an international meeting to keep you right up to date with the latest and greatest developments in their field. This week's special is the ASCO GI Symposium, held in Moscone, California, and brought to your ears from Melbourne. From two guys in their pyjamas. Who would much rather be in Moscone, California.

At any rate, updates abound in this OftiM special. Listen on so you too can crest the wave of Gastrointestinal Oncology!

Studies Discussed: NAPOLI 3, CHECKMATE 648 and 649 updates, SPOTLIGHT, Pemigatinib in FGFR mutant mCRC

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

24. Metastatic Renal Cell Cancer

Sat, 04 Feb 2023 19:00:02 GMT

Oncology for the Inquisitive Mind returns to its regular broadcasting schedule and discusses metastatic renal cell cancer (ccRCC). As not to be outdone, Josh takes a cultural tangent exploring the world of opera after seeing "The Hours" broadcast through Met: Live in HD. While Josh doesn't sing this episode, he highlights this opera's parallels with cancer patients undergoing treatment. To avoid losing sight of this podcast's purpose, Michael and Josh soon find their way. They discovered that metastatic renal cell carcinoma has many treatment options, including targeted therapy, immunotherapy, or even combining these two modalities! Tune in to find out where the evidence currently stands.

Links to studies discussed in this episode (subscription may be required):

CHECKMATE 214: https://www.nejm.org/doi/full/10.1056/nejmoa1712126

KEYNOTE-426: https://www.nejm.org/doi/full/10.1056/NEJMoa1816714

Other studies of interest:

CLEAR: https://www.nejm.org/doi/full/10.1056/NEJMoa2035716

CheckMate 9ER: https://www.nejm.org/doi/full/10.1056/nejmoa2026982

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

OncoSnacks 1: Mucositis

Tue, 31 Jan 2023 19:00:12 GMT

This is OncoSnacks, a new, fortnightly OftIM spinoff!

In this new bite-sized series, Michael and Josh try to sink their teeth into more slice-of-life topics, all to help you, our beloved listeners, digest some of the most common problems your patients will serve to you on a platter. This week, a treatment side effect that actually stops people eating (and making lame food-based puns as well): mucositis.

This common side effect of anti-cancer systemic therapy can have a major impact on patients quality of life, frequently leading to hospitalisations, significant morbidity and nasogastric tubes galore. But how do we manage such a troublesome problem? Listen on to find out!

eviQ reference guide on mucositis: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/oropharyngeal/210-oral-mucositis-and-stomatitis

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

23. Early Renal Cell Cancer

Sat, 28 Jan 2023 19:00:36 GMT

This week on Oncology for the Inquisitive Mind, Michael dons his cultural hat and begins with an Ode to the Kidneys, organs that are as much a muse for poets worldwide as the heart (probably). However, you didn't come to this podcast for excellent poetry being delivered with all the panache and misguided enthusiasm of a walrus stepping on a piece of LEGO, and Michael and Josh aim to deliver on this front. Our intrepid pair examine the controversial world of adjuvant treatment of clear cell renal cell cancers (ccRCC), an area of research littered with the ghosts of negative or equivocal studies. But, not every study can be a FLAURA or a DESTINY, and negative studies are just as important, so listen on to find out exactly what NOT to do. Truly, an OftIM first!

Links to studies discussed in this episode (subscription may be required):

ASSURE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591751/

KEYNOTE-564: https://www.nejm.org/doi/full/10.1056/NEJMoa2106391

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

22. Non Melanoma Skin Cancers - BCC and Merkle Cell Carcinoma

Sat, 21 Jan 2023 19:00:51 GMT

As the southern hemisphere basks in summer's beautiful warmth, Michael and Josh skip the beach to explore skin cancer. While melanoma usually takes centre stage in the oncological world, it is far less common than basal cell carcinoma or squamous cell carcinoma. Metastatic squamous cell carcinoma now has a viable and effective treatment option called cemiplimab. At the other end of the spectrum, Michael investigates the very rare cancer type Merkle Cell Carcinoma and how Avelumab has changed its treatment paradigm. Once again, it's immunotherapy at its best. So remember, while listening to our podcast, don't forget to wear a hat and apply sunscreen generously!

Links to studies discussed in this episode (subscription may be required):

Migden et al. (Cemiplimab): https://www.nejm.org/doi/10.1056/NEJMoa1805131?url_ver=Z39.88

JAVELIN Merkel 200 (Cohort B): https://jitc.bmj.com/content/9/7/e002646

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

21. Beginning a Career with Andrew Jensen

Sat, 14 Jan 2023 19:00:26 GMT

New year, new episode of Oncology for the Inquisitive Mind! After enjoying their holiday break, Josh and Michael dive right into 2023 with an episode especially aimed at trainees just about to start their new professional journey in Medical Oncology. Joined by an old friend, the wise-beyond-his-years Dr Andrew Jensen, they discuss life as a trainee, balancing work and life, and how to navigate the tough first few years of life in training, which can so often feel like being a bottle cast into a storm. Join us for an episode that may be light on hazard ratios and p values, but heavy on practical tips and wisdom, delivered in the tone of three dads drinking beer by a campfire...

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

20. Early-Stage Triple Negative Breast Cancer (TNBC)

Fri, 16 Dec 2022 21:04:17 GMT

Oncologists love pushing the limits of what is possible for our patients. To celebrate this and the 20th episode of Oncology for the Inquisitive Mind, Michael and Josh explore the heights of pioneering treatment for early-stage triple-negative breast cancer (TNBC). A notoriously resistant cancer with no known targetable lesions that affect younger women on average, The BrighTNess trial, Keynote 522 and Create-X show just how far the treatment landscape has changed in the last five years.

Tune into our final episode for the year! We will return in early 2023 with more content, interviews and hilarious banter.

On a final note, Dr Michael Fernando has been admitted to the Royal Australian College of Physicians (RACP), the equivalent of being board certified! Michael has completed this arduous training and is now a fully-fledged Medical Oncologist! Do not distress listeners. Despite no longer being a trainee, Michael will continue on as presenter and host extraordinaire for this podcast.

Links to studies discussed in this episode (subscription may be required):

BrighTNess trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-6/fulltext

Keynote 522: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549

Create-X: https://www.nejm.org/doi/full/10.1056/NEJMoa1612645

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

19. Early non-Small Cell Lung Cancer (NSCLC)

Sat, 10 Dec 2022 19:00:31 GMT

"I'm not in danger; I AM the danger!" So said Bryan Cranston's Walter White, and so too said early-stage lung cancer when confronted with adjuvant chemotherapy (maybe). In this episode, however, Josh and Michael follow in the footsteps of Hank Schrader, Steve Gomez et al., discussing ways to tackle one of the biggest killers in oncology. While we may not have found a way to control early-stage lung cancer, new developments are on the horizon, such as neoadjuvant chemo-immunotherapy and adjuvant osimertinib. So listen on, with the disclaimer that any similarities between Walter White and Jane Eyre are purely coincidental, no matter what Josh may argue...

Links to studies discussed in this episode (subscription may be required):

CHECKMATE-816: https://www.nejm.org/doi/10.1056/NEJMoa2202170

ADAURA: https://www.nejm.org/doi/full/10.1056/NEJMoa2027071

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

18. Metastatic Colorectal Cancer

Sat, 03 Dec 2022 19:30:42 GMT

In this episode, Josh and Mikey travel back millions of years to a time when dinosaurs roamed the Earth, as recent research has demonstrated, unmolested by cancer. Then they come crashing back to the present to discuss this week's topic, metastatic colorectal cancer. Will they discover secrets hidden across the aeons? Was the secret to cancer treatment hidden in the bones of our scaled precursors? No, of course not. But there will be a lot of information on the improving treatment of colorectal cancer, which has not taken millions of years to advance. Oh, and Michael does a passable Richard Attenborough.

Links to studies discussed in this episode (subscription may be required):

FIRE-3: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70330-4/fulltext

KEYNOTE 177: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699

BEACON: https://www.nejm.org/doi/full/10.1056/NEJMoa1908075

Epidemiological Study of Tumours in Dinosaurs: https://link.springer.com/article/10.1007/s00114-003-0473-9

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

17. Prostate Cancer with Dr Megan Crumbaker

Sat, 26 Nov 2022 21:00:38 GMT

Movember is an important event focussing on men's health, including cancer. Prostate cancer is the most common male cancer diagnosed in Australia and the second most common in American men. To highlight this and explore the pioneering treatments available, Michael and Josh interviewed the esteemed Dr Megan Crumbaker. Megan is a medical oncologist specialising in genitourinary cancer and works at The Kinghorn Cancer Centre and St. Vincents Health in Sydney, Australia. Dr Crumbaker completed her undergraduate at Rice University, Texas, before completing her medical training in Sydney and a PhD in prostate genomics through The Garvan Research Institute.

We discussed all things prostate oncology with Megan, including research, career, pioneering treatment options and all things prostate cancer. These treatment pearls are not to be missed by any budding oncologist!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

16. Metastatic Oesophageal/GOJ/Gastric Cancer

Sat, 19 Nov 2022 19:00:02 GMT

After looking at early upper gastrointestinal cancers last week, Michael and Josh take the logical next step and discuss the management of their metastatic cousins, the most unsavoury collection since Cassius and Brutus teamed up to assassinate their erstwhile friend Julius. And while our weapons against these cancers are limited, that will not stop our intrepid podcasting pair from taking a deep, rambling and irreverent dive into the dirty details. Friends! Oncologists! Countrymen! Lend us your ears!

Links to studies discussed in this episode (subscription may be required):

TOGA: https://www.thelancet.com/article/S0140-6736(10)61121-X/fulltext

CHECKMATE 649: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/fulltext

CHECKMATE 648: https://www.nejm.org/doi/full/10.1056/NEJMoa2111380

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

15. Early Gastric and Oesophageal Cancer

Sat, 12 Nov 2022 21:00:23 GMT

As we CROSS into another episode, Michael and Josh explore the world of early gastric cancer and esophageal cancer. Interestingly both these cancers have a higher incidence in Asia and North Africa. Your podcast hosts soon find early detection of these cancers can be difficult, often leading to treatment challenges not seen by other cancer streams, such as bowel or breast cancer. Unlike previous episodes, FLOT4 looks at perioperative chemotherapy and its benefits over the previous incumbent chemotherapy. Before we give anything more away, make sure to listen to this episode to understand the gold standard of care for these cancers. Likes to the trials below!

Links to studies discussed in this episode (subscription may be required):

CROSS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/fulltex

FLOT4: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

14. Advanced Ovarian Cancer

Sat, 05 Nov 2022 19:00:58 GMT

After the highs of their special interview with Dr Belinda Yeo on all things breast cancer, Josh and Michael crash back to their usual programming with a banter and dad-joke-filled journey through the treatment of advanced ovarian cancer. A notoriously insidious disease, ovarian cancer is responsible for not just significant mortality but soul-crushing morbidity as well. However, for some very special people, ovarian cancer does not stop them from reaching their goals, up to and including completing a triathlon! Listen on for the full, inspiring story!

Links to studies discussed in this episode (subscription may be required):

PAOLA-1: https://www.nejm.org/doi/full/10.1056/nejmoa1911361

AURELIA: https://ascopubs.org/doi/10.1200/jco.2013.51.4489

Leslie Medley-Russell, Ovarian Cancer Survivor: https://www.mdanderson.org/cancerwise/two-time-ovarian-cancer-survivor--never-give-up.h00-159148401.html

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

13. Breast Cancer with Dr Belinda Yeo

Sat, 29 Oct 2022 21:30:03 GMT

To celebrate the end of breast cancer awareness month, Michael and Josh are joined by Dr Belinda Yeo, an experienced oncologist specialising in treating breast cancer. Belinda trained at St Vincent's Hospital in Sydney, Australia, followed by the Royal Marsden Hospital in London. She now works at the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer and the prestigious Austin Hospital in Melbourne, Australia.

We discussed all things breast oncology with Belinda, including career path, research, patient-centred care and, of course, all the breast cancer treatment pearls for any budding oncologist!

This is one episode not to miss!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

12. Metastatic Pancreatic Cancer

Sat, 22 Oct 2022 19:00:00 GMT

In this episode, Josh and Michael take a step down from the dizzying heights of HER-2 positive breast cancer treatment and crash back to earth to metastatic pancreatic cancer, a topic that remains an unconquered Everest, mocking oncologists like that one kid who always stole Josh's lunch money in school... Don't worry; there will be no airing of childhood trauma here. Just two oncologists discussing treatments and casting a hopeful eye towards the future.

Links to studies discussed in this episode (subscription may be required):

ACCORD-11: https://www.nejm.org/doi/full/10.1056/nejmoa1011923

MPACT: https://www.nejm.org/doi/full/10.1056/nejmoa1304369

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

11. Metastatic HER2- Positive Breast Cancer

Sat, 15 Oct 2022 21:00:42 GMT

In part two of their HER2 breast cancer dive, Josh and Michael explore the optimistic world of metastatic breast cancer. Once a desolate space with limited options, HER2 metastatic breast cancer represents the frontier of targeted therapy, like the industrial age or landing on the moon. While neither Josh nor Mikey have been to the moon, these researchers have landed among the stars bringing hope and effective treatments to an aggressive tumour time that a decade ago would have had a very different story.

Links to studies discussed in this episode (subscription may be required):

CLEOPATRA: https://www.nejm.org/doi/full/10.1056/nejmoa1413513

Destiny-Beast03: https://www.nejm.org/doi/10.1056/NEJMoa2115022

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

10. Early HER2-Positive Breast Cancer

Sat, 08 Oct 2022 19:00:17 GMT

In this episode, Josh and Michael begin their second two-part expedition, this time exploring HER2-positive breast cancer, an area of oncology that has been much like your favourite Instagram or TikTok celebrity: at the forefront of the hottest new trends. Neither Josh nor Mikey have a favourite Instagram or TikTok celebrity because they are old and out of touch, but the shifts in HER2-positive breast cancer may be their favourite oncological TikTok celebrity. For the reasons behind such a stretched analogy, listen on!

Links to studies discussed in this episode (subscription may be required):

NeoSphere: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext

KATHERINE: https://www.nejm.org/doi/full/10.1056/nejmoa1814017

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

9. Metastatic Urothelial Cancer

Sat, 01 Oct 2022 19:00:56 GMT

In this episode, Josh and Michael once again tackle immunotherapy in its application to metastatic urothelial cancer. Some say immunotherapy should be used up front. Others say that it should be used when all previous treatments have failed. And still, others are wondering about that Richard Nixon/Spock impression from last week and how it could be topped. For answers to all those questions and more, you'll have to listen on...

Links to papers discussed in this episode (subscription may be required):

JAVELIN-100: https://www.nejm.org/doi/full/10.1056/NEJMoa2002788

KEYNOTE 045: https://www.nejm.org/doi/full/10.1056/nejmoa1613683

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

8. ESMO 2022 Highlights

Sat, 24 Sep 2022 22:00:48 GMT

In this extraordinary episode, Josh and Michael continue their journey to the earth's centre and the unknown with more European Society of Medical Oncology (ESMO) highlights.

Since last week, Michael has realised that his French needs a bit of work, so they stuck to their guns and avoided google translate. Josh feels they should work on their Spanish to prepare for ESMO in Madrid in 2023. But before these dashing young Doctors get too excited for next year, more pivotal studies must be reported for your enjoyment! This episode focuses on colorectal, and Michael dabbles in some genitourinary and skin research.

Find us @InquisitiveOnc for fun oncology facts and links to the latest episodes!

All abstracts discussed in this episode are available from https://oncologypro.esmo.org. ESMO membership may be required.

Colorectal: FRESCO-2, NICHE-2, MOUNTAINEER, CAIRO5

Genitourinary: RADICALS-HD, COSMIC 313;

Skin: SWOG1801; Neoadjuvant Cemiplimab (NEJM)

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

7. ESMO 2022 Highlights

Sat, 17 Sep 2022 20:00:30 GMT

In this very special episode, Josh and Michael hope to fulfil their fantasy of attending the European Society of Medical Oncology's (ESMO) yearly Congress, where they rub elbows with oncology's biggest movers and shakers; learn about the latest groundbreaking studies; and, in Michael's case, speak French with an accent lifted from a Monty Python sketch. The fact that they were stuck at home for the entire conference won't stand in the way of them from highlighting some of the best, most exciting studies presented in Paris.

Find us @InquisitiveOnc for fun oncology facts and links to the latest episodes!

All abstracts discussed in this episode are available from https://oncologypro.esmo.org. ESMO membership may be required.

Lung: ADAURA, CODEBREAK 200, INCREASE, IPSOS, Checkmate 816, APPLE

Breast: BELLINI, TROPiCS-02

Upper GI: LEAP-002, PRODIGE-65-UCGI-36-GEMPAX, RLY-4008

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Fanfare theme courtesy of StudioKolomna: https://pixabay.com/users/studiokolomna-2073170/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

6. Hepatobiliary Cancer

Sat, 10 Sep 2022 20:00:08 GMT

"Hepatobiliary cancer, the final frontier." So begins our double-headed sojourn into two of the most challenging to-treat cancers many oncologists will encounter, but one that ends on a surprisingly positive note. Also, there's a cameo that absolutely no one will see coming...

Links to studies discussed in this episode (subscription may be required):

TOPAZ-1: https://evidence.nejm.org/doi/full/10.1056/EVIDoa220001

IMbrave150: https://www.nejm.org/doi/10.1056/NEJMoa1915745

Barcelona Liver Cancer Staging: https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fb5943f9-9201-4128-848a-626d744c651f/gr1_lrg.jpg

Source: Reig M, et al. "BCLC strategy for prognosis prediction and treatment recommendation: the 2022 Update." Journal of Hepatology. November 2021. Available from: https://doi.org/10.1016/j.jhep.2021.11.018

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

5. Early Hormone Receptor-Positive Breast Cancer

Sat, 03 Sep 2022 20:00:46 GMT

In episode 5, Michael and Josh dive into the complex world of hormone receptor-positive breast cancer. While early-stage breast cancer boasts fantastic cure rates many other cancers can only dream of, this evolving space must contend with multiple players, including aromatase inhibitors, tamoxifen and now abemaciclib (CDK 4/6 inhibitor). How best to approach adjuvant endocrine therapy is difficult, but Michael and Josh are on the case!

Links to papers discussed in this episode (subscription may be required):

SOFT/TEXT: Prudence et al. (2018): https://www.nejm.org/doi/full/10.1056/NEJMoa1803164

MonarchE: Johnston et al. (2020): https://pubmed.ncbi.nlm.nih.gov/32954927/

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

4. Metastatic Non-Small Cell Lung Cancer

Sat, 27 Aug 2022 20:00:00 GMT

Four episodes already! How time flies when you're having fun. In this episode, Josh and Michael discuss metastatic lung cancer, an area of oncology where a survival benefit of a few months generates cheers, tears and standing ovations. So what happens when studies start to improve patients' outcomes by YEARS? I don't know, but there were almost certainly minds that were thoroughly blown. Join us for this most optimistic of episodes!

Links to papers discussed in this episode (subscription may be required):

KEYNOTE-189: https://www.nejm.org/doi/full/10.1056/nejmoa1801005

FLAURA: https://www.nejm.org/doi/full/10.1056/NEJMoa1913662

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

3. Mesothelioma

Sat, 20 Aug 2022 20:00:20 GMT

In this episode, Michael and Josh discuss the scourge that is metastatic mesothelioma. This genuinely awful disease continues to inflict significant mortality and morbidity on patients exposed to asbestos worldwide. One of our more grim episodes thus far, but never fear; we have still crammed in more dad jokes than one can wave a bag of chemotherapy at.

Links to papers discussed in this episode (subscription may be required):

Vogelzang et al (2003): https://ascopubs.org/doi/10.1200/jco.2003.11.136

CHECKMATE-743: https://www.thelancet.com/article/S0140-6736(20)32714-8/fulltext

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Editor's Note: the background noise is wind from a storm that hit Melbourne on the day of recording. It is not a cat being put through a blender

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

2. Metastatic Melanoma

Sat, 13 Aug 2022 20:00:06 GMT

In this episode, Josh and Michael discuss the incredible story of the treatment of metastatic melanoma, the immunotherapy revolution, and why this relegated a perfectly decent targeted therapy to second place on the podium. Join us for a titanic battle on a par with Macbeth vs Macduff, Rocky Balboa vs Apollo Creed, or Regina George vs that bus...

Links to papers discussed (subscription may be required):

CHECKMATE-067: https://www.nejm.org/doi/full/10.1056/nejmoa1910836

COMBI-D: https://www.nejm.org/doi/full/10.1056/NEJMoa1904059

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Cover art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

1. Hormone Sensitive Prostate Cancer

Sat, 06 Aug 2022 22:53:56 GMT

In their inaugural episode, Michael and Josh discuss one of the most common cancers a budding oncologist will encounter: prostate cancer. But is there more to this cancer than meets the eye? Will they make sense of the whole confusing mess? Is this whole podcasting thing way too much for them to handle? Listen on to find out!

Links to papers discussed (subscription may be required):

CHAARTED: https://www.nejm.org/doi/full/10.1056/nejmoa1503747

ENZAMET: https://www.nejm.org/doi/full/10.1056/nejmoa1903835

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Cover art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Introducing: Oncology for the Inquisitive Mind

Sun, 31 Jul 2022 20:00:11 GMT

Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.